var title_f14_25_14736="Lung transplant procedures";
var content_f14_25_14736=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 658px\">",
"   <div class=\"ttl\">",
"    Number of lung transplant procedures reported by year and procedure type",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 638px; height: 450px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure includes both transplants reported to the ISHLT Registry from organ-exchange organizations in countries with a data-sharing agreement, as well as transplants reported voluntarily from centers in countries without a specific data-sharing agreement. Therefore, this figure may not fully represent the total number of procedures worldwide or the trend in activity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report--2011. J Heart Lung Transplant 2011; 30:1104. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_25_14736=[""].join("\n");
var outline_f14_25_14736=null;
var title_f14_25_14737="Corner stretch";
var content_f14_25_14737=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Corner stretch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 267px; height: 541px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stand in the corner with your arms in a 90-90 position and each forearm braced against adjacent walls. Move one foot forward and gently lean forward until you feel a stretch in your chest and shoulders. Hold for 30 seconds. Release the pressure for 5 to 10 seconds and repeat. Perform 3 repetitions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_25_14737=[""].join("\n");
var outline_f14_25_14737=null;
var title_f14_25_14738="Patient information: Heavy periods (The Basics)";
var content_f14_25_14738=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/4/36930\">",
"         Patient information: Absent or irregular periods (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/8/143\">",
"         Patient information: Endometrial ablation (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/25/11666\">",
"         Patient information: Painful periods (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/52/21314\">",
"         Patient information: Uterine fibroids (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/35/23094\">",
"         Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/20/20804\">",
"         Patient information: Uterine fibroids (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Heavy periods (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/heavy-periods-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H213375407\">",
"      <span class=\"h1\">",
"       What causes heavy periods?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on your body and individual situation. There might be nothing wrong with you at all. Things that cause heavy periods include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        One of your ovaries not releasing an egg during one or more months",
"       </li>",
"       <li>",
"        Growths in the uterus called &ldquo;fibroids&rdquo;",
"       </li>",
"       <li>",
"        A bleeding disorder that prevents your blood from clotting normally",
"       </li>",
"       <li>",
"        Side effects of some medicines, such as some types of birth control or blood thinners",
"       </li>",
"       <li>",
"        A problem with your thyroid (a gland that makes hormones)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H213375414\">",
"      <span class=\"h1\">",
"       How much bleeding is normal when I have my period?",
"      </span>",
"      &nbsp;&mdash;&nbsp;During a normal period, bleeding lasts between 3 and 7 days. Most women lose between 2 and 3 tablespoons of blood during that time. Losing more than 5 tablespoons of blood during a period can be a sign of a problem. Blood loss is hard to measure with a spoon. But you can look for other signs that your periods are too heavy, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Having to change a pad or tampon every 1 or 2 hours",
"       </li>",
"       <li>",
"        Passing large lumps of blood, called clots",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H213375421\">",
"      <span class=\"h1\">",
"       Is my bleeding an emergency?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or go to the emergency room right away if you soak through 4 or more pads or tampons in 2 hours. Any bleeding is an emergency if you are pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H213375428\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor or nurse if you:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Are pregnant or think you may be pregnant",
"       </li>",
"       <li>",
"        Have a period that lasts for more than 7 days",
"       </li>",
"       <li>",
"        Soak through a pad or tampon every 1 or 2 hours, and this happens every time you have a period",
"       </li>",
"       <li>",
"        Need to use both pads and tampons at the same time because you are bleeding so much",
"       </li>",
"       <li>",
"        Need to change your pad or tampon during the night",
"       </li>",
"       <li>",
"        Pass clots that are bigger than 1 inch wide",
"       </li>",
"       <li>",
"        Bleed in between periods.",
"       </li>",
"       <li>",
"        Have irregular periods that happen more or less often than once a month",
"       </li>",
"       <li>",
"        Have pain and bad cramps in your lower belly before or while you are bleeding",
"       </li>",
"       <li>",
"        Are having trouble getting pregnant",
"       </li>",
"       <li>",
"        Have any of symptoms listed above and are low in iron. Signs of being low in iron include:",
"       </li>",
"       <li>",
"        Feeling weak",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Feeling very tired",
"       </li>",
"       <li>",
"        Having headaches",
"       </li>",
"       <li>",
"        Having trouble breathing when you exercise",
"       </li>",
"       <li>",
"        Feeling your heart beat too fast when you exercise",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H213375435\">",
"      <span class=\"h1\">",
"       Are there tests I should have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse will decide which tests you should have based on your age, symptoms, and individual situation. There are lots of tests, but you may not need any.",
"     </p>",
"     <p>",
"      Here are the most common tests doctors use to find the cause of heavy periods:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests &ndash; Blood tests can check if you are pregnant, or have hormonal changes, a bleeding disorder, low iron levels, or other problems.",
"       </li>",
"       <li>",
"        Endometrial biopsy &ndash; For this test, the doctor will take a sample of tissue from inside your uterus. The sample can be viewed under a microscope to look for problems.",
"       </li>",
"       <li>",
"        Pelvic ultrasound &ndash; This test uses sound waves to make a picture of your uterus, ovaries, and vagina. The pictures can show if you have fibroids or other growths.",
"       </li>",
"       <li>",
"        Hysteroscopy &ndash; For this test, the doctor will use a small instrument to look inside your uterus.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H213375442\">",
"      <span class=\"h1\">",
"       How are heavy periods treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on what is causing your heavy periods and whether you want to get pregnant soon. You may not need treatment. If you do, treatments might include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Birth control methods that use hormones. These make your period lighter or stop your periods completely. They come as:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Pills",
"       </li>",
"       <li>",
"        Skin patches",
"       </li>",
"       <li>",
"        A ring that you put inside your vagina",
"       </li>",
"       <li>",
"        Shots that you get every 3 months",
"       </li>",
"       <li>",
"        An intrauterine device (IUD), a plastic device that your doctor inserts into your uterus.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines that thicken blood and slow bleeding",
"       </li>",
"       <li>",
"        Medicines that reduce swelling, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sold as Motrin&reg; and Advil&reg;) or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/5/19541?source=see_link\">",
"         mefenamic acid",
"        </a>",
"        (sold as Ponstel&reg;)",
"       </li>",
"       <li>",
"        Medicines that contain a hormone called &ldquo;progestin.&rdquo; These are taken for a week or so every few months.",
"       </li>",
"       <li>",
"        Medicines that make the ovaries stop working for a short time",
"       </li>",
"       <li>",
"        Surgery to remove fibroids or other growths",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H213375449\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/52/21314?source=see_link\">",
"       Patient information: Uterine fibroids (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/4/36930?source=see_link\">",
"       Patient information: Absent or irregular periods (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/25/11666?source=see_link\">",
"       Patient information: Painful periods (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/8/143?source=see_link\">",
"       Patient information: Endometrial ablation (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/35/23094?source=see_link\">",
"       Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=see_link\">",
"       Patient information: Uterine fibroids (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?14/25/14738?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15420 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-B4DFEB0FC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_25_14738=[""].join("\n");
var outline_f14_25_14738=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H213375407\">",
"      What causes heavy periods?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H213375414\">",
"      How much bleeding is normal when I have my period?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H213375421\">",
"      Is my bleeding an emergency?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H213375428\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H213375435\">",
"      Are there tests I should have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H213375442\">",
"      How are heavy periods treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H213375449\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/4/36930?source=related_link\">",
"      Patient information: Absent or irregular periods (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/8/143?source=related_link\">",
"      Patient information: Endometrial ablation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/35/23094?source=related_link\">",
"      Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/25/11666?source=related_link\">",
"      Patient information: Painful periods (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=related_link\">",
"      Patient information: Uterine fibroids (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/52/21314?source=related_link\">",
"      Patient information: Uterine fibroids (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_25_14739="Periesophageal lymph nodes EUS";
var content_f14_25_14739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Benign and malignant periesophageal lymph nodes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic ultrasound images showing benign (left panel) and malignant (right panel) appearing periesophageal lymph node in a patient with histologically proven esophageal adenocarcinoma. Characteristics of the benign lymph node are its mixed echogenicity, irregular border, elongated shape, and &lt;10 mm in width. In contrast, the malignant lymph node is echopoor, has a smooth border, round shape, and &gt;10 mm in width.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Enrique Vazquez-Sequeiros, MD and Maurits J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_25_14739=[""].join("\n");
var outline_f14_25_14739=null;
var title_f14_25_14740="Zinc oxide: Patient drug information";
var content_f14_25_14740=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Zinc oxide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"     see \"Zinc oxide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/11/31922?source=see_link\">",
"     see \"Zinc oxide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ammens&reg; Original Medicated [OTC];",
"     </li>",
"     <li>",
"      Ammens&reg; Shower Fresh [OTC];",
"     </li>",
"     <li>",
"      Balmex&reg; [OTC];",
"     </li>",
"     <li>",
"      Boudreaux's&reg; Butt Paste [OTC];",
"     </li>",
"     <li>",
"      Critic-Aid Skin Care&reg; [OTC];",
"     </li>",
"     <li>",
"      Desitin&reg; Creamy [OTC];",
"     </li>",
"     <li>",
"      Desitin&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F235779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zincofax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691826",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat dry skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692076",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703147",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to zinc oxide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696250",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use. Do not wash your hands after use if putting this on your hand.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is used on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12157 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-3BFBD2B80D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_25_14740=[""].join("\n");
var outline_f14_25_14740=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235778\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235779\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013350\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013349\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013354\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013355\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013357\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013352\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013353\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013358\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013359\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=related_link\">",
"      Zinc oxide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/11/31922?source=related_link\">",
"      Zinc oxide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_25_14741="Glycolipid inclusion bodies";
var content_f14_25_14741=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F54672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F54672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plastic embedded renal tissue demonstrating glycolipid inclusion bodies in distal tubules, with relative sparing of proximal tubules, and interstitial fibrosis (toluidine blue stain, original magnification X80)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 366px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine 2002; 81:122. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_25_14741=[""].join("\n");
var outline_f14_25_14741=null;
var title_f14_25_14742="Sinus tachycardia";
var content_f14_25_14742=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sinus tachycardia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/25/14742/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/25/14742/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/25/14742/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/25/14742/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/25/14742/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/25/14742/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/25/14742/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus tachycardia is a rhythm in which the rate of impulses arising from the sinoatrial (SA) node is elevated. The normal heart rate has been considered historically to range from 60 to 100 beats per minute (bpm), with sinus tachycardia being defined as a sinus rhythm with a rate exceeding 100 bpm. However, the \"normal\" heart rate varies in part with age. The heart rate is usually between 110 and 150 bpm in infants, with gradual slowing over the next six years. The resting sinus rate in older children and adults is approximately 65 to 85 bpm, with some authors suggesting a slowing in older age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14742/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2086?source=see_link\">",
"     \"Normal sinus rhythm and sinus arrhythmia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a review in which the heart rate was electrocardiographically recorded in 500 normal individuals, the mean afternoon heart rate for men and women was 70 to 75 beats per minute with two standard deviation limits of 43 and 93 beats per minute in men and 52 and 94 beats per minute for women; there was no significant change between ages 50 and 80 (",
"    <a class=\"graphic graphic_table graphicRef77746 \" href=\"UTD.htm?37/10/38059\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14742/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology, diagnosis, and treatment of sinus tachycardia, including inappropriate sinus tachycardia, will be reviewed here. Sinoatrial reentry supraventricular tachycardia that involves tissue from the SA node is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=see_link\">",
"     \"Overview of the acute management of tachyarrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of sinus tachycardia are the normal response to exercise and conditions in which catecholamine release is physiologically enhanced: flight, fright, anger, or stress. A long list of other factors may be responsible in selected cases including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hyperthyroidism",
"     </li>",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Effective volume depletion",
"     </li>",
"     <li>",
"      Anxiety",
"     </li>",
"     <li>",
"      Pheochromocytoma",
"     </li>",
"     <li>",
"      Sepsis",
"     </li>",
"     <li>",
"      Anemia",
"     </li>",
"     <li>",
"      Hypotension and shock",
"     </li>",
"     <li>",
"      Pulmonary embolism",
"     </li>",
"     <li>",
"      Acute coronary ischemia and myocardial infarction",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      Chronic pulmonary disease",
"     </li>",
"     <li>",
"      Hypoxia",
"     </li>",
"     <li>",
"      Exposure to stimulants (nicotine, caffeine) or illicit drugs",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus tachycardia is often asymptomatic, although the patient may complain of a rapid heartbeat. However, problems can occur in patients with organic heart disease. In this setting, a very rapid heart rate can:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decrease the cardiac output by shortening ventricular filling time",
"     </li>",
"     <li>",
"      Exacerbate coexisting myocardial",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      valvular heart disease",
"     </li>",
"     <li>",
"      Increase myocardial oxygen consumption",
"     </li>",
"     <li>",
"      Reduce coronary blood flow",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ELECTROCARDIOGRAPHIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The P waves in a sinus tachycardia have a normal morphology unless there is concurrent atrial disease. The PR interval tends to decrease with increasing heart rate, unless the rate causes the atrioventricular (AV) node to be relatively refractory; in this setting, the PR interval may lengthen. Young adults can reach heart rates above 200 beats per minute during exercise, a response that decreases with age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14742/abstract/6\">",
"     6",
"    </a>",
"    ]. In general, the maximum heart rate can be estimated from the following formula:",
"   </p>",
"   <p>",
"    &nbsp;Maximal heart rate,",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    = 220 - age",
"   </p>",
"   <p>",
"    The maximum heart rate depends on intrinsic factors and pulse pressure in the SA nodal artery as well as on the effects of sympathetic and parasympathetic inputs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of sinus tachycardia is usually easily established from the ECG. However, the P waves may be difficult to identify at heart rates above 140 beats per minute, since they are often superimposed on the preceding T wave (",
"    <a class=\"graphic graphic_waveform graphicRef78938 \" href=\"UTD.htm?5/41/5780\">",
"     waveform 1",
"    </a>",
"    ). As a result, a sinus tachycardia can be confused with a paroxysmal supraventricular tachycardia or atrial flutter with 2:1 block.",
"   </p>",
"   <p>",
"    Carotid sinus massage, other vagal maneuvers, or intravenous AV nodal blocking agents (eg, adenosine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ) may help in the identification of the arrhythmia by inducing one or more of the following (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Slowing the sinus rate to allow proper identification of the sinus P waves",
"     </li>",
"     <li>",
"      Causing transient AV nodal block to make atrial flutter with 2:1 block apparent",
"     </li>",
"     <li>",
"      Termination of a paroxysmal supraventricular tachycardia (atrioventricular nodal reentrant tachycardia or atrioventricular reentrant tachycardia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Inappropriate sinus tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inappropriate sinus tachycardia (IST), also called chronic nonparoxysmal sinus tachycardia, is an unusual condition that occurs in individuals without apparent heart disease or other cause for sinus tachycardia, such as hyperthyroidism or fever [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14742/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Affected patients have an elevated resting heart rate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an exaggerated heart rate response to exercise; many patients have both.",
"   </p>",
"   <p>",
"    The cause of IST is unknown, but abnormal autonomic control is thought to be important. Many patients with IST work in the healthcare field.",
"   </p>",
"   <p>",
"    One study suggested that this tachycardia is related to a primary sinus node abnormality, characterized by a high intrinsic heart rate, depressed efferent cardiovagal reflex, and beta-adrenergic hypersensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14742/abstract/8\">",
"     8",
"    </a>",
"    ]. Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    and enhanced vagal tone shift the pacemaker site along the crista terminalis, while adenosine slows the rate, but has little effect on the pacemaker focus and on activation sequence [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14742/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The shifting site of the SA pacemaker within the large epicardial SA nodal complex can be problematic when ablation is considered as a therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14742/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Postural orthostatic tachycardia syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postural orthostatic tachycardia syndrome (POTS) occurs predominantly in young women with normal hearts, who have a normal resting heart rate and an exaggerated postural sinus tachycardia elicited by upright tilt table testing in the absence of orthostatic hypotension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29159?source=see_link\">",
"     \"Postural tachycardia syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;No therapy is required for a physiologic sinus tachycardia and, in most settings, treatment is directed at the underlying disease. Acute myocardial infarction is sufficiently important to warrant a few specific comments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Acute myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus tachycardia occurs in one-third or more of patients with acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14742/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Although this is seen soon after the patient arrives in the coronary care unit, the heart rate usually declines over time to a level that reflects the degree of activation of the sympathetic nervous system. Patients with persistent sinus tachycardia usually have larger infarcts that are more often anterior and a marked impairment in left ventricular function, which is associated with substantial morbidity, a high early mortality, and an increased 30 day mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14742/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. In addition, sinus tachycardia may increase the size of ischemic injury and infarction due at least in part to increased oxygen consumption.",
"   </p>",
"   <p>",
"    In view of the prognostic importance of sinus tachycardia, it is important to exclude other causes of this arrhythmia. These include fear, anxiety, fever, pericarditis, and medications. Heart failure, hypoxia, recurrent ischemia, and hypotension should be aggressively treated. In the absence of identifiable triggers, sinus tachycardia in acute myocardial infarction can be treated with cautious beta blockade. However, most patients will receive such therapy independent of the tachycardia since early beta blocker administration is part of routine management of acute myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=see_link\">",
"     \"Beta blockers in the management of acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Inappropriate sinus tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inappropriate sinus tachycardia (IST) can continue for months or years and may produce troublesome symptoms, typically palpitations, shortness of breath, dizziness, and decreased exercise capacity. Treatment of symptomatic IST is frequently challenging, often with suboptimal results. We suggest using ivabradine (5 mg twice daily) for patients with symptomatic IST. Addition of a beta blocker may be effective if the cause of IST is overactivity of the sympathetic nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14742/abstract/17\">",
"     17",
"    </a>",
"    ]. However, control of the heart rate (HR) is difficult if the sinus tachycardia results from depressed vagal activity. Limited published data exist on the use of non-dihydropyridine calcium channel blockers (eg, verapamil) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14742/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ivabradine is a drug that decreases the depolarizing I",
"    <sub>",
"     f",
"    </sub>",
"    current in the sinoatrial node, thereby decreasing the heart rate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14742/abstract/18\">",
"     18",
"    </a>",
"    ]. A large randomized study of ivabradine versus placebo in patients with coronary artery disease and left ventricular dysfunction supports the safety and efficacy of ivabradine for lowering heart rates (although these patients did not have IST) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14742/abstract/19\">",
"     19",
"    </a>",
"    ]. Ivabradine is not currently available in the United States or Canada.",
"   </p>",
"   <p>",
"    Additionally, ivabradine appears to be an effective treatment option for patients with IST [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14742/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among a single center cohort of 20 patients with IST who were treated on an open-label basis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      (mean dose 157 mg daily) for 4 weeks, followed by immediate conversion (no washout phase) to ivabradine (5 mg twice daily titrated to 7.5 mg twice daily in all patients), patients had significant reductions in resting HR with both drugs (mean HR 93 and 90 beats per minute with metoprolol ivabradine, respectively, compared with 114 beats per minute at baseline) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/25/14742/abstract/22\">",
"       22",
"      </a>",
"      ]. However, patients reported significantly fewer symptoms when taking ivabradine.",
"     </li>",
"     <li>",
"      In a double-blind, placebo-controlled study of 21 patients with IST, patients received either ivabradine (5 mg twice daily) or placebo for six weeks, followed by a washout period and cross over to the other treatment for six additional weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?14/25/14742/abstract/21\">",
"       21",
"      </a>",
"      ]. Symptom evaluation and HR assessment using supine, standing, and exercise electrocardiography were performed at the beginning and end of each phase of the study. Ivabradine use resulted in the following outcomes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Improvement in symptoms in all patients, with 14 patients (67 percent) reporting elimination of &gt;70 percent of symptoms and 9 patients (43 percent) reporting complete resolution of symptoms while on ivabradine.",
"     </li>",
"     <li>",
"      Significant reductions in resting HR (from 88 to 76 beats per minute), standing HR (from 108 to 92 beats per minute), and HR during effort (176 to 158 beats per minute).",
"     </li>",
"     <li>",
"      Significant increases in exercise time (7.2 to 8.9 minutes).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If pharmacologic therapy for IST is unsuccessful, radiofrequency catheter ablation can be attempted. The goal is to modify the sinus node without ablating it completely, which would then necessitate pacemaker implantation. However, if the tachycardia is a reflex response related to postural orthostatic tachycardia syndrome (POTS), ablation may lead to worsening symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33431?source=see_link&amp;anchor=H11#H11\">",
"     \"Catheter ablation of atrial tachycardia\", section on 'Inappropriate sinus tachycardia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29159?source=see_link\">",
"     \"Postural tachycardia syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/34/5666?source=see_link\">",
"       \"Patient information: Tachycardia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10700258\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sinus tachycardia is a rhythm in which the rate of impulses arising from the sinoatrial (SA) node is elevated. The normal heart rate has been considered historically to range from 60 to 100 beats per minute (bpm), with sinus tachycardia being defined as a sinus rhythm with a rate exceeding 100 bpm. However, the \"normal\" heart rate varies in part with age. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common causes of sinus tachycardia are the normal response to exercise and conditions in which catecholamine release is physiological. Most commonly sinus tachycardia is due to fever, volume depletion, hypoxia, or anxiety. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sinus tachycardia is most often asymptomatic, though it may exacerbate underlying cardiac pathology because of the increase in myocardial oxygen demand and decrease in diastolic filling time associated with the tachycardia.",
"     </li>",
"     <li>",
"      Sinus tachycardia is generally confirmed by electrocardiography (ECG) after a rapid pulse is identified on physical examination. Since the tachycardia arises from the SA node, the P waves should have a normal or near normal appearance on ECG and should occur in a regular fashion. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Electrocardiographic features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with a physiologic sinus tachycardia, no therapy is required; rather, treatment is directed at any underlying etiology. However, since persistent tachycardia in a patient with acute myocardial ischemia can result in larger infarcts and a more marked impairment in left ventricular function, treatment of sinus tachycardia with beta blockers is appropriate in most patients. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inappropriate sinus tachycardia (IST) is an unusual condition of unknown etiology that occurs in individuals without apparent heart disease or other cause for sinus tachycardia. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Inappropriate sinus tachycardia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of symptomatic IST is challenging, often with suboptimal results. When available, we suggest using ivabradine (5 mg twice daily) for patients with symptomatic IST (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The medication is not currently available in the United States or Canada. Addition of a beta blocker may be effective if the cause of IST is overactivity of the sympathetic nervous system. However, ivabradine appears to be the most promising and efficacious treatment for IST.",
"     </li>",
"     <li>",
"      For patients with persistent symptomatic IST despite optimal medical therapy, radiofrequency catheter ablation may be attempted. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Inappropriate sinus tachycardia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14742/abstract/1\">",
"      Scott O, Williams GJ, Fiddler GI. Results of 24 hour ambulatory monitoring of electrocardiogram in 131 healthy boys aged 10 to 13 years. Br Heart J 1980; 44:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14742/abstract/2\">",
"      Brodsky M, Wu D, Denes P, et al. Arrhythmias documented by 24 hour continuous electrocardiographic monitoring in 50 male medical students without apparent heart disease. Am J Cardiol 1977; 39:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14742/abstract/3\">",
"      Bjerregaard P. Mean 24 hour heart rate, minimal heart rate and pauses in healthy subjects 40-79 years of age. Eur Heart J 1983; 4:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14742/abstract/4\">",
"      Spodick DH. Normal sinus heart rate: sinus tachycardia and sinus bradycardia redefined. Am Heart J 1992; 124:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14742/abstract/5\">",
"      Spodick DH, Raju P, Bishop RL, Rifkin RD. Operational definition of normal sinus heart rate. Am J Cardiol 1992; 69:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14742/abstract/6\">",
"      Sheffield LT, Holt JH, Reeves TJ. Exercise graded by heart rate in electrocardiographic testing for angina pectoris. Circulation 1965; 32:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14742/abstract/7\">",
"      Bauernfeind RA, Amat-Y-Leon F, Dhingra RC, et al. Chronic nonparoxysmal sinus tachycardia in otherwise healthy persons. Ann Intern Med 1979; 91:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14742/abstract/8\">",
"      Morillo CA, Klein GJ, Thakur RK, et al. Mechanism of 'inappropriate' sinus tachycardia. Role of sympathovagal balance. Circulation 1994; 90:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14742/abstract/9\">",
"      Krahn AD, Yee R, Klein GJ, Morillo C. Inappropriate sinus tachycardia: evaluation and therapy. J Cardiovasc Electrophysiol 1995; 6:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14742/abstract/10\">",
"      Glatter KA, Cheng J, Dorostkar P, et al. Electrophysiologic effects of adenosine in patients with supraventricular tachycardia. Circulation 1999; 99:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14742/abstract/11\">",
"      Lee RJ, Kalman JM, Fitzpatrick AP, et al. Radiofrequency catheter modification of the sinus node for \"inappropriate\" sinus tachycardia. Circulation 1995; 92:2919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14742/abstract/12\">",
"      DeSanctis RW, Block P, Hutter AM Jr. Tachyarrhythmias in myocardial infarction. Circulation 1972; 45:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14742/abstract/13\">",
"      Crimm A, Severance HW Jr, Coffey K, et al. Prognostic significance of isolated sinus tachycardia during first three days of acute myocardial infarction. Am J Med 1984; 76:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14742/abstract/14\">",
"      Severance HW Jr, Morris KG, Wagner GS. Criteria for early discharge after acute myocardial infarction: validation in a community hospital. Arch Intern Med 1982; 142:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14742/abstract/15\">",
"      McNeer JF, Wallace AG, Wagner GS, et al. The course of acute myocardial infarction. Feasibility of early discharge of the uncomplicated patient. Circulation 1975; 51:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14742/abstract/16\">",
"      Becker RC, Burns M, Gore JM, et al. Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice. The National Registry of Myocardial Infarction (NRMI-2) Participants. Am Heart J 1998; 135:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14742/abstract/17\">",
"      Femen&iacute;a F, Baranchuk A, Morillo CA. Inappropriate sinus tachycardia: current therapeutic options. Cardiol Rev 2012; 20:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14742/abstract/18\">",
"      DiFrancesco D, Camm JA. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 2004; 64:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14742/abstract/19\">",
"      Tendera M, Talajic M, Robertson M, et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). Am J Cardiol 2011; 107:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14742/abstract/20\">",
"      Cal&ograve; L, Rebecchi M, Sette A, et al. Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia. Heart Rhythm 2010; 7:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14742/abstract/21\">",
"      Cappato R, Castelvecchio S, Ricci C, et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol 2012; 60:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14742/abstract/22\">",
"      Ptaszynski P, Kaczmarek K, Ruta J, et al. Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive to previous pharmacological therapy. Europace 2013; 15:116.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1074 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-6DAE62D42F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_25_14742=[""].join("\n");
var outline_f14_25_14742=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10700258\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ELECTROCARDIOGRAPHIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Inappropriate sinus tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Postural orthostatic tachycardia syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Inappropriate sinus tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10700258\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1074\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1074|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/10/38059\" title=\"table 1\">",
"      Normal heart rates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1074|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?5/41/5780\" title=\"waveform 1\">",
"      ECG strip sinus tachycardia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33431?source=related_link\">",
"      Catheter ablation of atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2086?source=related_link\">",
"      Normal sinus rhythm and sinus arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=related_link\">",
"      Overview of the acute management of tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/34/5666?source=related_link\">",
"      Patient information: Tachycardia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29159?source=related_link\">",
"      Postural tachycardia syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_25_14743="Esterified estrogen and methyltestosterone: Drug information";
var content_f14_25_14743=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Esterified estrogen and methyltestosterone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/9/8342?source=see_link\">",
"    see \"Esterified estrogen and methyltestosterone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F167642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Covaryx&reg;;",
"     </li>",
"     <li>",
"      Covaryx&reg; H.S.;",
"     </li>",
"     <li>",
"      EEMT&trade;;",
"     </li>",
"     <li>",
"      EEMT&trade; HS",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F167652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Estrogen and Androgen Combination",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F167644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Vasomotor symptoms associated with menopause:",
"     </b>",
"     Adults: Females: Oral: Usual dosage range (based on esterified estrogen component): 0.625-1.25 mg once daily. Lowest dose that will control symptoms should be chosen, normally given 3 weeks on and 1 week off.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3182138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15838020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15838021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F167631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Esterified estrogen 0.625 mg and methyltestosterone 1.25 mg; esterified estrogens 1.25 mg and methyltestosterone 2.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Covaryx&reg; H.S.: Esterified estrogens 0.625 mg and methyltestosterone 1.25 [contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Covaryx&reg;: Esterified estrogens 1.25 mg and methyltestosterone 2.5 mg [contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     EEMT&trade; HS: Esterified estrogen 0.625 mg and methyltestosterone 1.25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     EEMT&trade;: Esterified estrogen 1.25 mg and methyltestosterone 2.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F167617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9518205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food at same time each day.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F167632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of moderate-to-severe vasomotor symptoms associated with menopause not improved by estrogens alone",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F167658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Estratest&reg; may be confused with Eskalith&reg;, Estratab&reg;, Estratest&reg; H.S.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Estratest&reg; H.S. may be confused with Eskalith&reg;, Estratab&reg;, Estratest&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F167650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to the Estrogens (Esterified) and the Testosterone monographs.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F167635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to estrogens, methyltestosterone, or any component of the formulation; undiagnosed abnormal vaginal bleeding; DVT or PE (current or history of); active or history of arterial thromboembolic disease (eg, stroke, MI); carcinoma of the breast (known, suspected or history of), except in appropriately selected patients being treated for metastatic disease; estrogen-dependent tumor; hepatic dysfunction or disease; pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F167621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;  Breast cancer:",
"     <b>",
"      [U.S. Boxed Warning]: Based on data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in postmenopausal women using conjugated estrogens (CE) in combination with medroxyprogesterone acetate (MPA).",
"     </b>",
"     This risk may be associated with duration of use and declines once combined therapy is discontinued (Chlebowski, 2009). The risk of invasive breast cancer was decreased in postmenopausal women with a hysterectomy using CE only, regardless of weight. However, the risk was not significantly decreased in women at high risk for breast cancer (family history of breast cancer, personal history of benign breast disease) (Anderson, 2012). An increase in abnormal mammogram findings has also been reported with estrogen alone or in combination with progestin therapy. Estrogen use may also lead to severe hypercalcemia in patients with breast cancer and bone metastases; discontinue estrogen if hypercalcemia occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent dementia. In the Women&rsquo;s Health Initiative Memory Study (WHIMS), an increased incidence of dementia was observed in women &ge;65 years of age taking CE alone or in combination with MPA.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endometrial carcinoma:",
"     <b>",
"      [U.S. Boxed Warning]: The use of unopposed estrogen in women with an intact uterus is associated with an increased risk of endometrial cancer. The addition of a progestin to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Adequate diagnostic measures, including endometrial sampling if indicated, should be performed to rule out malignancy in postmenopausal women with undiagnosed abnormal vaginal bleeding.",
"     </b>",
"     Estrogens may exacerbate endometriosis. Malignant transformation of residual endometrial implants has been reported posthysterectomy with unopposed estrogen therapy. Consider adding a progestin in women with residual endometriosis posthysterectomy.  This combination product contains an estrogen and androgen; it does not contain a progestin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inherited thrombophilia: Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho, 2010; van Vlijmen, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased; use with caution in patients with familial defects of lipoprotein metabolism.  Testosterone may also alter serum cholesterol; use caution with history of MI or coronary artery disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian cancer: Postmenopausal estrogen therapy and combined estrogen/progesterone therapy may increase the risk of ovarian cancer; however, the absolute risk to an individual woman is small. Although results from various studies are not consistent, risk does not appear to be significantly associated with the duration, route, or dose of therapy. In one study, the risk decreased after 2 years following discontinuation of therapy (M&oslash;rch, 2009). Although the risk of ovarian cancer is rare, women who are at an increased risk (eg, family history) should be counseled about the association (NAMS, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polycythemia: Testosterone may increase hematocrit requiring dose adjustment or discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use caution in patients with asthma; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent cardiovascular disease.",
"     </b>",
"     Using data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of deep vein thrombosis (DVT) and stroke has been reported with CE and an increased risk of DVT, stroke, pulmonary emboli (PE) and myocardial infarction (MI) has been reported with CE with MPA in postmenopausal women. Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of venous thromboembolism (VTE). Risk factors should be managed appropriately; discontinue use if adverse cardiovascular events occur or are suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including including cardiac or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Epilepsy: Use caution with epilepsy; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: Use of postmenopausal estrogen may be associated with an increased risk of gallbladder disease requiring surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic dysfunction: Estrogens are poorly metabolized in patients with hepatic dysfunction. Use caution with a history of cholestatic jaundice associated with prior estrogen use or pregnancy. Discontinue if jaundice develops or if acute or chronic hepatic disturbances occur. Prolonged use of high doses of androgens has been associated with serious hepatic effects (peliosis hepatis, hepatic neoplasms, cholestatic hepatitis, jaundice).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic hemangiomas: Use with caution in patients with hepatic hemangiomas; may exacerbate disease. Use is contraindicated with hepatic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hereditary angioedema: Exogenous estrogens may exacerbate angioedema symptoms in women with hereditary angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypocalcemia: Use with caution in patients with severe hypocalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Migraine: Use caution with migraine; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use with caution in patients with porphyria; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SLE: Use with caution in patients with SLE; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use testosterone with caution in elderly patients; may be at greater risk for fluid retention, transaminase elevations, and cardiac problems. Use estrogens with caution in elderly postmenopausal women due to potential of increased risk of breast and endometrial cancers, and risk of dementia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Prior to puberty, estrogens may cause premature closure of the epiphyses, premature breast development in girls, or gynecomastia in boys. Vaginal bleeding and vaginal cornification may also be induced in girls.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnant women:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens should not be used during pregnancy.",
"     </b>",
"     Prescribing information states that the use of estrogens and progestins during early pregnancy may cause teratogenic effects. This is based on information from females exposed to diethylstilbestrol (DES)",
"     <i>",
"      in utero",
"     </i>",
"     and later developed a rare form of vaginal or cervical cancer. Product labeling also cites older literature associating limb reduction defects with oral contraceptives. In general, the use of estrogen and progestin, as in combination hormonal contraceptives, have not been associated with teratogenic effects when inadvertently taken early in pregnancy. However, testosterone may cause adverse effects, including masculinization of the female fetus, if used during pregnancy. This combination product is specifically contraindicated for use in pregnant women.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, should be discontinued at least 4-6 weeks prior to elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tartrazine: Some products may contain tartrazine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Products containing estrogens (esterified) and methyltestosterone have not received pre-market approval by the FDA. Information in this monograph has been expanded beyond the available prescribing information",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Risks vs benefits:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should be used for the shortest duration possible at the lowest effective dose consistent with treatment goals.",
"     </b>",
"     Before prescribing estrogen therapy to postmenopausal women, the risks and benefits must be weighed for each patient. Women should be informed of these risks and benefits, as well as possible effects of progestin when added to estrogen therapy. Patients should be reevaluated as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from Women&rsquo;s Health Initiative (WHI) studies, which evaluated oral CE 0.625 mg with or without MPA 2.5 mg relative to placebo in postmenopausal women. Other combinations and dosage forms of estrogens and progestins were not studied.",
"     <b>",
"      Outcomes reported from clinical trials using CE with or without MPA should be assumed to be similar for other doses and other dosage forms of estrogens and progestins until comparable data becomes available.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F167649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F167625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Androgens may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women.  Management: Monitor for reduced growth hormone efficacy. A larger somatropin dose may be required to reach treatment goal.  This interaction does not appear to apply to non-orally administered estrogens (e.g., transdermal, vaginal ring).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Androgens may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F167626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F167638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens should not be used during pregnancy.",
"     </b>",
"     This product is specifically contraindicated during pregnancy. Refer to the Estrogens (Esterified) monograph and the Testosterone monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12708386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     This product is specifically contraindicated in breast-feeding women. Refer to the Estrogens (Esterified) monograph and the Testosterone monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F167639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with food at same time each day.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F167637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Covaryx HS Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.625-1.25 mg (100): $104.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Covaryx Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.25-2.5 mg (100): $124.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (EEMT HS Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.625-1.25 mg (100): $135.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (EEMT Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.25-2.5 mg (100): $166.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Est Estrogens-Methyltest Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.25-2.5 mg (100): $213.75",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F167629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Routine physical examination that includes blood pressure and Papanicolaou smear, breast exam, mammogram. Monitor for signs of endometrial cancer. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding. Monitor for loss of vision, sudden onset of proptosis, diplopia, migraine; signs and symptoms of thromboembolic disorders; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias; thyroid function in patients on thyroid hormone replacement therapy; liver function tests; signs of virilization (eg, hirsutism, acne, deepening of voice, clitoromegaly)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Menopausal symptoms: Assess need for therapy at 3- to 6-month intervals",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F167640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Estratest (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F167620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Conjugated estrogens: Activate estrogen receptors (DNA protein complex) located in estrogen-responsive tissues. Once activated, regulate transcription of certain genes leading to observed effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Testosterone: Increases synthesis of DNA, RNA, and various proteins in target tissues",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F167634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to the Estrogens (Esterified) and the Testosterone monographs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Chlebowski RT, Aragaki AK, et al, \"Conjugated Equine Oestrogen and Breast Cancer Incidence and Mortality in Postmenopausal Women With Hysterectomy: Extended Follow-Up of the Women's Health Initiative Randomised Placebo-Controlled Trial,\"",
"      <i>",
"       Lancet Oncol,",
"      </i>",
"      2012,13(5):476-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14743/abstract-text/22401913/pubmed\" id=\"22401913\" target=\"_blank\">",
"        22401913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Limacher M, Assaf AR, et al, \"Effects of Conjugated Equine Estrogen In Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial.\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 291(14):1701-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14743/abstract-text/15082697/pubmed\" id=\"15082697\" target=\"_blank\">",
"        15082697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"Certain Estrogen-Androgen Combination Drugs; Drugs for Human Use; Drug Efficacy Study Implementation; Amendment and Opportunity for Hearing,\"",
"      <i>",
"       Federal Register",
"      </i>",
"      68(71):17953-57.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chlebowski RT, Kuller LH, Prentice RL, et al, \"Breast Cancer After Use of Estrogen Plus Progestin in Postmenopausal Women,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(6):573-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14743/abstract-text/19196674/pubmed\" id=\"19196674\" target=\"_blank\">",
"        19196674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSancho MT, Dorff T, and Rand JH, \"Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,\"",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 2010, 21(6):534-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14743/abstract-text/20581664/pubmed\" id=\"20581664\" target=\"_blank\">",
"        20581664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hsia J, Langer RD, Manson JE, et al, \"Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2006, 166(3):357-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14743/abstract-text/16476878/pubmed\" id=\"16476878\" target=\"_blank\">",
"        16476878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khurana RN, LaBree LD, Scott G, et al, \"Esterified Estrogens Combined With Methyltestosterone Raise Intraocular Pressure In Postmenopausal Women,\"",
"      <i>",
"       Am J Ophthalmol",
"      </i>",
"      , 2006, 142(3):494-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14743/abstract-text/16935599/pubmed\" id=\"16935599\" target=\"_blank\">",
"        16935599",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu J, Allgood A, Derogatis LR, et al, \"Safety and Efficacy of Low-Dose Esterified Estrogens and Methyltestosterone, Alone or Combined, for the Treatment of Hot Flashes in Menopausal Women: A Randomized, Double-Blind, Placebo-Controlled Study,\"",
"      <i>",
"       Fertil Steril",
"      </i>",
"      , 2011, 95(1):366-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14743/abstract-text/20850731/pubmed\" id=\"20850731\" target=\"_blank\">",
"        20850731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      M&oslash;rch LS, L&oslash;kkegaard E, Andreasen AH, et al, &ldquo;Hormone Therapy and Ovarian Cancer,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2009, 302(3):298-305.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14743/abstract-text/19602689/pubmed\" id=\"19602689\" target=\"_blank\">",
"        19602689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ness RB, Albano JD, McTiernan A, et al, \"Influence of Estrogen Plus Testosterone Supplementation on Breast Cancer,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2009, 169(1):41-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14743/abstract-text/19139322/pubmed\" id=\"19139322\" target=\"_blank\">",
"        19139322",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      North American Menopause Society [NAMS], \"The 2012 Hormone Therapy Position Statement of The North American Menopause Society,\"",
"      <i>",
"       Menopause",
"      </i>",
"      , 2012, 19(3):257-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14743/abstract-text/22367731/pubmed\" id=\"22367731\" target=\"_blank\">",
"        22367731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips EH, Ryan S, Ferrari R, et al, \"Estratest And Estratest HS (Esterified Estrogens and Methyltestosterone) Therapy: A Summary of Safety Surveillance Data, January 1989 to August 2002,\"",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2003, 25(12):3027-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14743/abstract-text/14749144/pubmed\" id=\"14749144\" target=\"_blank\">",
"        14749144",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al, &ldquo;Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principle Results From the Women's Health Initiative Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(3):321-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14743/abstract-text/12117397/pubmed\" id=\"12117397\" target=\"_blank\">",
"        12117397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shumaker SA, Legault C, Rapp SR, et al, &ldquo;Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(20):2651-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14743/abstract-text/12771112/pubmed\" id=\"12771112\" target=\"_blank\">",
"        12771112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suthers K, \"Estratest is Not Approved by the Food and Drug Administration,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2007, 167(2):205-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14743/abstract-text/17242325/pubmed\" id=\"17242325\" target=\"_blank\">",
"        17242325",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tamimi RM, Hankinson SE, Chen WY, et al, \"Combined Estrogen And Testosterone Use And Risk Of Breast Cancer In Postmenopausal Women,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2006, 166(14):1483-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14743/abstract-text/16864758/pubmed\" id=\"16864758\" target=\"_blank\">",
"        16864758",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Food and Drug Administration, Department of Health and Human Services, &ldquo;WHIMS Study on Estrogen/Progestin,&rdquo; May 27, 2003. Available at",
"      <a href=\"file://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm\" target=\"_blank\">",
"       file://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al, \"Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(8):2055-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14743/abstract-text/21659542/pubmed\" id=\"21659542\" target=\"_blank\">",
"        21659542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8740 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-02DD474397-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_25_14743=[""].join("\n");
var outline_f14_25_14743=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708758\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167642\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167652\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167644\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3182138\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838020\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15838021\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167631\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167617\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9518205\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167632\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167658\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167650\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167635\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167621\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167649\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167625\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167626\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167638\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12708386\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167639\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167637\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167629\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167640\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167620\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167634\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8740\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8740|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/9/8342?source=related_link\">",
"      Esterified estrogen and methyltestosterone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_25_14744="Pulmonary vein velocity schematic";
var content_f14_25_14744=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68801%7ECARD%2F87117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68801%7ECARD%2F87117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schematic of normal pulmonary venous flow velocity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 403px; height: 342px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pulmonary venous velocity time integrals in systole (VTIs) and diastole (VTId) are determined by planimetry. The VTIs consists of two peaks due to early and late systolic atrial filling; the VTId contains a short pulmonary venous flow reversal after atrial contraction. A predominantly negative VTIs (VTIs &lt;0) translates into VTIs/VTId &lt;0, compatible with significant mitral regurgitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Seiler C, Aeschbacher BC, Meier B. J Am Coll Cardiol 1998; 31:1383.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 676px\">",
"   <div class=\"ttl\">",
"    Pulsed wave Doppler pulmonary venous flow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 656px; height: 454px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    From an apical four-chamber view, a pulse wave sample volume is positioned at the entrance of the right superior pulmonary vein showing the characteristic systolic \"s\" (1) and diastolic \"d\" (2) wave velocities in addition to flow reversal during atrial contraction \"a\" (3) wave.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_25_14744=[""].join("\n");
var outline_f14_25_14744=null;
var title_f14_25_14745="Pulmonary complications after autologous hematopoietic cell transplantation";
var content_f14_25_14745=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pulmonary complications after autologous hematopoietic cell transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/25/14745/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/25/14745/contributors\">",
"     Robert J Kaner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/25/14745/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/25/14745/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/25/14745/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/25/14745/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/25/14745/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/25/14745/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous hematopoietic cell transplantation is performed with increasing frequency, particularly as salvage therapy after high dose chemotherapy for recurrent lymphoma, leukemia, multiple myeloma, germ cell tumors, and neuroblastoma. A variety of pulmonary complications have been described with these procedures, occurring either early (within the first several weeks) or late (more than one month) after transplantation. This distinction can guide the differential diagnosis and clinical evaluation of these disorders.",
"   </p>",
"   <p>",
"    The term \"hematopoietic cell transplantation\" (HCT) will be used throughout this review as a general term to cover transplantation of progenitor cells from any source (eg, bone marrow, peripheral blood, umbilical cord blood). Otherwise, the source of such cells will be specified (eg, autologous peripheral blood progenitor cell transplantation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Significant pulmonary complications are a leading cause of morbidity and mortality following HCT. The pulmonary complications of autologous HCT will be reviewed here. The pulmonary complications of",
"    <strong>",
"     allogeneic",
"    </strong>",
"    HCT are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=see_link\">",
"     \"Pulmonary complications after allogeneic hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNIQUE OF AUTOLOGOUS HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, autologous bone marrow was obtained from the patient by multiple iliac crest aspirations under general anesthesia. The marrow was usually treated in vitro with a procedure designed to purge residual tumor cells, and then cryopreserved with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33123?source=see_link\">",
"     dimethyl sulfoxide",
"    </a>",
"    or glycerol. Some of the acute side effects of marrow infusion, such as dyspnea, may be attributable to the cryopreservative.",
"   </p>",
"   <p>",
"    The procedure is similar with peripheral blood hematopoietic cell transplantation, which is currently more common, except that the cells are collected by leukapheresis, avoiding the need for general anesthesia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COMPARISON WITH ALLOGENEIC HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pulmonary complications of autologous HCT share many of the features associated with allogeneic HCT, but there are also important differences. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=see_link\">",
"     \"Pulmonary complications after allogeneic hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cellular interactions between graft and host cells are largely eliminated with autologous transplantation. Thus, graft rejection and graft-versus-host disease are insignificant and do not require prevention or treatment. The net effect is reduced need for pharmacologic immunosuppression after the transplant.",
"     </li>",
"     <li>",
"      Posttransplant pneumonitis associated with cytomegalovirus (CMV) infection is rarely a problem after autologous transplantation, in contrast to its high incidence after allogeneic transplantation (",
"      <a class=\"graphic graphic_picture graphicRef50365 \" href=\"UTD.htm?26/26/27048\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Certain other opportunistic infections, such as Toxoplasma gondii, are very rare after autologous transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/1,2\">",
"       1,2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Why there is a much lower incidence of Toxoplasma and certain other infections after autologous transplants is not completely understood. In animal models and in patients with HIV infection, host defense against Toxoplasma is dependent upon helper T-cells and the ability to release mediators such as interleukin-2 and interferon gamma from mononuclear cells in response to infection. Thus, the less profound defect in cell-mediated immunity after autologous transplantation could explain the reduced incidence of many opportunistic infections such as toxoplasmosis and CMV pneumonitis. However, abnormalities in T-cell function can persist for many months after engraftment in both types of transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The infectious complications during the first four to six weeks after both allogeneic and autologous transplants are primarily due to bacterial and fungal infections secondary to neutropenia. In addition, intensive treatment of the underlying malignancy with chemotherapy and radiotherapy (particularly to the chest) predisposes to serious noninfectious posttransplant pulmonary complications, including diffuse alveolar hemorrhage and drug or radiation toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EARLY COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the first several weeks after autologous or peripheral stem cell transplant, the incidence of pulmonary disease due to noninfectious and infectious causes is about equal [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Acute respiratory failure necessitating mechanical ventilation is usually due to diffuse alveolar hemorrhage, fungal infection, pulmonary edema (cardiogenic or noncardiogenic), or idiopathic interstitial pneumonitis (idiopathic pneumonia syndrome). Viral infection causes acute respiratory failure in children more often than in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mortality of acute respiratory failure after HCT is high in both adults and children. However, an aggressive diagnostic approach and a trial of mechanical ventilation are indicated, since some patients will survive [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44598?source=see_link&amp;anchor=H5#H5\">",
"     \"Intensive care for oncology patients: Short-term prognosis\", section on 'Bone marrow transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Respiratory infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory infections during the first few weeks after HCT are primarily due to bacteria or fungi, and are usually associated with neutropenia. Bacterial infections are frequently due to Gram negative bacteria or to Staphylococcus or Streptococcus species. The possibility of infection with penicillin-resistant pneumococci should be entertained. Vancomycin-resistant gram positive organisms, including Staph aureus, have been reported in the immunocompromised host. Empiric antibiotic therapy must include adequate coverage for these organisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fungal disease should be suspected in patients with prolonged neutropenia or previous glucocorticoid therapy, particularly if nodular infiltrates are present on the chest radiograph. Chest CT scanning adds to the sensitivity of the plain radiograph for detecting fungal infection, since nodules may be seen on CT scan weeks before they are visible on chest radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulmonary infections with Aspergillus are most common [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/10\">",
"     10",
"    </a>",
"    ], but endemic fungi are also possible pathogens. Disseminated Candida infections occur in over 3 percent of autologous transplant recipients; survival appears to be better in children than adults [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/11\">",
"     11",
"    </a>",
"    ]. Mucormycosis is rare following autologous HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=see_link\">",
"     \"Diagnosis of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=see_link\">",
"     \"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link\">",
"     \"Mucormycosis (zygomycosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of Pneumocystis jirovecii (P. carinii) pneumonia and Herpes simplex viral infections has been dramatically reduced by effective prophylaxis, usually with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    . Most studies of pulmonary infections after bone marrow transplantation have focused on patients who received allogeneic transplants, so the literature regarding infection following autologous transplants is less well-developed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=see_link&amp;anchor=H29#H29\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\", section on 'Pneumocystis carinii (jirovecii) prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=see_link&amp;anchor=H194946070#H194946070\">",
"     \"Pulmonary complications after allogeneic hematopoietic cell transplantation\", section on 'Pulmonary infections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37754268\">",
"    <span class=\"h2\">",
"     Aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of aspiration may be increased by mucositis, a frequent complication of HCT, and treatment of the associated pain with opiates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29306?source=see_link&amp;anchor=H598154#H598154\">",
"     \"Supportive care after hematopoietic cell transplantation\", section on 'Mucositis and nutritional support'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pulmonary edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary edema, both cardiogenic and noncardiogenic, may be multifactorial in etiology.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute cardiac toxicity can occur after treatment with high dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , used in many conditioning regimens. This is particularly problematic in patients with preexisting cardiac dysfunction, but patients with normal cardiac function pretransplant may also develop subclinical cardiac dysfunction after autologous transplantation.",
"     </li>",
"     <li>",
"      Chronic cardiac toxicity due to previous anthracycline administration may become clinically apparent only after the patient is exposed to large volumes of intravenous fluid in the immediate posttransplant period.",
"     </li>",
"     <li>",
"      Total body irradiation may be contributory in patients with preexisting heart disease. In addition, intercurrent infections and anemia may also add to the stress on a previously well-compensated dysfunctional heart.",
"     </li>",
"     <li>",
"      Pleuropericarditis, possibly secondary to prior radiation therapy, can occur and may be accompanied by atrial tachyarrhythmias or pericardial tamponade.",
"     </li>",
"     <li>",
"      Cardiac arrest secondary to noncardiogenic pulmonary edema has been reported immediately following the infusion of autologous marrow [",
"      <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/13,14\">",
"       13,14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diffuse alveolar damage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse alveolar damage (DAD) is the pathologic correlate of the acute respiratory distress syndrome (ARDS). DAD can be caused by the sepsis syndrome, as in the immunocompetent host, aspiration, or it can reflect prior therapy with agents known to have pulmonary toxicity&nbsp;(",
"    <a class=\"graphic graphic_picture graphicRef57964 \" href=\"UTD.htm?30/4/30793\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef65804 \" href=\"UTD.htm?40/11/41145\">",
"     picture 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Toxicity from chemotherapy and/or radiotherapy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4871?source=see_link\">",
"     \"Acute respiratory distress syndrome: Prognosis and outcomes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of the underlying infection and supportive care are no different from those used for other causes of ARDS. Streptococcal sepsis is particularly common in children after autologous HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/15\">",
"     15",
"    </a>",
"    ]. Resistant streptococci are increasing in frequency in the general population, and this may affect the antibiotic regimens used to treat such infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15960344\">",
"    <span class=\"h2\">",
"     Engraftment syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The engraftment syndrome is generally suspected when a patient develops fever and a rash approximately 9 to 16 days following autologous HCT. The engraftment syndrome is associated with increased capillary permeability that occurs during the neutrophil recovery phase following HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. It is attributed to release of proinflammatory cytokines, such as interleukin (IL)-2, tumor necrosis factor-&alpha;, interferon-&gamma;, IL-8 and IL-6, macrophage colony-stimulating factor (M-CSF), and erythropoietin, that precedes neutrophil engraftment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Criteria for the syndrome are not well-established: some sets of criteria require a close temporal relationship with neutrophil recovery (eg, onset within one to five days of recovery of neutrophils in the peripheral blood) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/16,21\">",
"     16,21",
"    </a>",
"    ], while others uncouple the onset of the syndrome and neutrophil recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/20\">",
"     20",
"    </a>",
"    ]. The incidence of the engraftment syndrome varies with the criteria used, the underlying disease that necessitated HCT, and the chemotherapeutic agents used prior to HCT; reported numbers range from 12 to 60 percent; however, the frequency of patients with symptoms severe enough to consider treatment is probably much lower [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/16,19,20\">",
"     16,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical manifestations include noninfectious fever (&gt;38.3&thinsp;&deg;C), maculo-papular rash mimicking acute graft-versus-host disease, diffuse radiographic pulmonary opacities, and diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/16\">",
"     16",
"    </a>",
"    ]. Weight gain, edema, ascites, and hypoalbuminemia are common accompanying features. The reported frequency of diffuse opacities on chest radiograph ranges from 11 to 37 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/19,22\">",
"     19,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The engraftment syndrome is usually self-limited. Appropriate cultures should be obtained, and empiric antibiotics are frequently administered. For patients with progressive or symptomatic engraftment syndrome, systemic glucocorticoids are initiated; however, this is rarely required [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/16,19,20\">",
"     16,19,20",
"    </a>",
"    ]. The optimal dose and duration of glucocorticoid therapy is not known; reported doses range from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    0.5 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]. After a clinical response, the glucocorticoids are tapered, usually over 7 to 10 days. Prompt defervescence usually follows the administration of glucocorticoids (within 1 to 2 days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Toxicity from chemotherapy and/or radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary toxicity from the combination of previous chemotherapy and radiotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the pretransplant conditioning regimen may become clinically apparent in the immediate posttransplant period [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/23\">",
"     23",
"    </a>",
"    ]. Patients typically present with fever, dyspnea, cough, and hypoxemia. Chest radiographs can show patchy or diffuse mixed interstitial and alveolar infiltrates. Biopsy findings are nonspecific and include DAD, type II alveolar epithelial cell atypia and hyperplasia, interstitial pneumonitis, and thickening of the interstitium with early fibrosis. There is usually minimal acute inflammation.",
"   </p>",
"   <p>",
"    After infection has been adequately excluded with invasive procedures, corticosteroids (1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) are usually employed for the treatment of lung toxicity. There are, however, no prospective studies to document the efficacy of glucocorticoid therapy in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=see_link\">",
"     \"Radiation-induced lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21990?source=see_link\">",
"     \"Cyclophosphamide pulmonary toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37415?source=see_link\">",
"     \"Busulfan-induced pulmonary injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28327?source=see_link\">",
"     \"Nitrosourea-induced pulmonary injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diffuse alveolar hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse alveolar hemorrhage (DAH) is associated with a high mortality. Prompt diagnosis is important, since retrospective studies suggest that glucocorticoid treatment may favorably alter the outcome (see below). Affected patients usually present with tachypnea, dyspnea,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypoxemia developing during the first two weeks after autologous HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/25\">",
"     25",
"    </a>",
"    ]. Gross hemoptysis is rare, and was noted in only 15 percent of patients in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/26\">",
"     26",
"    </a>",
"    ]. The progression of signs and symptoms can be rapid, and often occurs over less than 48 hours. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link\">",
"     \"The diffuse alveolar hemorrhage syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chest radiographs typically reveal a single or multiple patchy interstitial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    alveolar infiltrates, which then become more widespread (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63710 \" href=\"UTD.htm?23/18/23845\">",
"     image 1",
"    </a>",
"    ). The central portions of the lung are initially involved, particularly the mid- and lower lung zones [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/27\">",
"     27",
"    </a>",
"    ]. The radiographic findings may precede the development of symptoms by several days.",
"   </p>",
"   <p>",
"    One small study suggested that chest CT is more sensitive than plain radiographs for the detection of alveolar hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/28\">",
"     28",
"    </a>",
"    ]. However, bronchoalveolar lavage, with the classic diagnostic finding of progressively bloodier aliquots of lavage fluid, is usually necessary for a presumptive diagnosis after fungal and other infections have been excluded.",
"   </p>",
"   <p>",
"    The pathophysiology of DAH is poorly understood [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/29\">",
"     29",
"    </a>",
"    ]. Thrombocytopenia or the presence of a coagulopathy is not directly related to its development, although current practice is to correct these abnormalities when present. Similarly, there is no evidence for a role of infectious agents. Although the pathogenesis of pulmonary hemorrhage remains obscure, two possible risk factors have been identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of posttransplant hemorrhage is increased in patients with lymphoma who received pretransplant external beam radiotherapy to the chest for the treatment of bulky disease [",
"      <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/30\">",
"       30",
"      </a>",
"      ]. However, this should not prevent lymphoma patients with disease in the chest from undergoing autologous HCT, since their overall relapse-free survival is not reduced compared to patients with lymphoma in the absence of pulmonary involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A single study linked pretransplant airways inflammation, as assessed by an enhanced percentage of neutrophils",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      eosinophils in the initial aliquot of bronchoalveolar lavage fluid, to an increased risk of posttransplant pulmonary hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Survival after pulmonary hemorrhage has been poor, particularly in patients who develop respiratory failure requiring mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/30\">",
"     30",
"    </a>",
"    ]. Anecdotal and retrospective reports suggest improved survival in patients treated with corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. One retrospective study, for example, found that approximately 10 percent of patients developed diffuse alveolar hemorrhage after HCT. Survival was significantly higher in the 43 patients who had been treated with high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (33 versus 9 percent in those treated with no or only low-dose steroids) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In view of the high mortality associated with untreated hemorrhage, we recommend the administration of systemic glucocorticoids after infection has been adequately excluded, recognizing the limitations of current data regarding efficacy. Usual treatment regimens begin with 0.5 to 1.0 g of intravenous (pulse)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    daily for several days, followed by a rapid taper of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    over approximately two weeks.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/42/30373?source=see_link\">",
"     Recombinant human factor VIIa",
"    </a>",
"    has been used in the management of DAH, but experience is limited. Off-label treatment with recombinant factor VIIa after DAH cannot be recommended, except as part of a clinical trial. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=see_link&amp;anchor=H23#H23\">",
"     \"Therapeutic uses of recombinant coagulation factor VIIa\", section on 'Pulmonary hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     LATE COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The category of late pulmonary complications refers to those disorders developing more than one month after autologous HCT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Respiratory infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory infections occurring in this period are still often due to bacterial and fungal organisms, even after initial neutropenia has resolved. These infections may be related to inadequate specific antibody production and to other more subtle immunologic abnormalities. Persistent mass-like lesions that do not respond to empiric antibiotics should be evaluated for focal fungal or mycobacterial disease, but recurrent cancer must also be considered in patients with lymphoma or solid tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mycobacterial infections, both typical and atypical, can also occur during this period. The frequency of mycobacterial infection can reach 5 percent in patients from populations with a high background prevalence [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/35\">",
"     35",
"    </a>",
"    ]. Treatment with antimycobacterial drugs is highly effective in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Viral infections of the lung can occur following autologous HCT, but with lower morbidity and mortality (due to a lesser degree of immunosuppression) than seen after allogeneic transplantation. Cytomegalovirus, for example, can be the cause of interstitial pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=see_link&amp;anchor=H194946070#H194946070\">",
"     \"Pulmonary complications after allogeneic hematopoietic cell transplantation\", section on 'Pulmonary infections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other respiratory viral infections can also develop as a late complication following autologous HCT, including Herpes simplex virus, Varicella zoster (after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    prophylaxis is discontinued), and influenza. Adenovirus and respiratory syncytial virus pulmonary infections are rare after autologous transplant, in contrast to patients treated with allogeneic HCT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Restrictive lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of pulmonary function in patients receiving autologous transplants show that diffusing capacity and total lung capacity are typically decreased from pretransplant values; however, many patients with lung function abnormalities are not symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. Observed decrements in lung function are usually due to high dose chemotherapy given prior to the transplant (particularly if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    is used) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/41,42\">",
"     41,42",
"    </a>",
"    ], but also can be associated with relapse of the underlying malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28327?source=see_link\">",
"     \"Nitrosourea-induced pulmonary injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21990?source=see_link\">",
"     \"Cyclophosphamide pulmonary toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, breast cancer patients treated with high dose",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"      cyclophosphamide",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"      cisplatin",
"     </a>",
"     /BCNU",
"    </span>",
"    followed by autologous HCT showed a &gt;30 percent decrease in diffusing capacity (DLCO) on average by week 18 posttransplant in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/41\">",
"     41",
"    </a>",
"    ]. Symptomatic patients treated with glucocorticoids (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 2 weeks, followed by a 6 week taper) had a 17 percent improvement in DLCO.",
"   </p>",
"   <p>",
"    A second study of 150 consecutive high risk breast cancer patients found that delayed pulmonary toxicity syndrome (manifested by a moderate to severe reduction in diffusing capacity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary symptoms in the absence of infection) occurred in 72 percent of patients treated with standard induction chemotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , 5-fluorouracil) and high dose cyclophosphamide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    chemotherapy with peripheral progenitor cell support [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/43\">",
"     43",
"    </a>",
"    ]. Recognition of pulmonary toxicity and treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    effected a gradual improvement in DLCO, so that after 2 years it did not differ significantly from that in patients who received standard dose chemotherapy, and no deaths were attributable to chemotherapy-related lung disease.",
"   </p>",
"   <p>",
"    Interstitial lung disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary fibrosis may develop rapidly after transplantation or may take months to years to manifest:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Idiopathic interstitial pneumonitis (idiopathic pneumonia syndrome) occurring early after autologous HCT has a high mortality in both children and adults, particularly if acute respiratory failure develops [",
"      <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=see_link&amp;anchor=H17#H17\">",
"       \"Pulmonary complications after allogeneic hematopoietic cell transplantation\", section on 'Idiopathic pneumonia syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Idiopathic eosinophilic pneumonia leading to fatal lung disease has been reported after autologous transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interstitial pneumonitis and fibrosis may be delayed for months or years after treatment; the term \"delayed pulmonary toxicity syndrome\" has been proposed to describe affected individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who develop end-stage pulmonary fibrosis may be candidates for lung transplantation if there has been no evidence of recurrent malignancy within two to five years prior to listing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Bronchiolitis obliterans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although obstructive airways disease is much less common after autologous than after allogeneic HCT, fatal bronchiolitis obliterans (also referred to as obliterative bronchiolitis) has been reported following autologous transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=see_link&amp;anchor=H464750157#H464750157\">",
"     \"Pulmonary complications after allogeneic hematopoietic cell transplantation\", section on 'Airflow obstruction and bronchiolitis obliterans'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PREDICTING COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatal pulmonary complications have been described following high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    and autologous stem cell transplant for treatment of non-Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/48\">",
"     48",
"    </a>",
"    ]. Older patients and those with pre-existing abnormal lung function appear to have increased risk. Preliminary observations suggest that pulmonary function testing and measurement of plasma levels of the profibrogenic cytokine transforming growth factor-beta (TGF-beta) may help to stratify patients for risk of pulmonary complications after HCT. Patients with pretransplant pulmonary function abnormalities, for example, appear to be at increased risk of nonfatal pulmonary complications following HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/49\">",
"     49",
"    </a>",
"    ]. Similarly, patients with elevated levels of proinflammatory cytokines, including transforming growth factor-alpha (TGF-alpha) and granulocyte-macrophage colony stimulating factor (GM-CSF), in their BAL fluid appear to be at increased risk of pulmonary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/50\">",
"     50",
"    </a>",
"    ]. However, this risk should not preclude otherwise eligible patients from being transplanted. Pretransplant screening bronchoscopy may be useful for the early detection of asymptomatic pulmonary problems [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/32\">",
"     32",
"    </a>",
"    ], but this approach has not yet gained general acceptance.",
"   </p>",
"   <p>",
"    One report evaluated the predictive value of measuring TGF-beta levels prior to high dose chemotherapy for breast cancer in patients receiving autologous HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/51\">",
"     51",
"    </a>",
"    ]. Those patients with elevated levels had an increased risk of posttransplant pulmonary toxicity and hepatic veno-occlusive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/51\">",
"     51",
"    </a>",
"    ]. The predictive value for either of these complications was 90 percent or more when the plasma TGF-beta concentration was more than 2 SD above the mean in controls. On the other hand, patients who did not develop these complications had TGF-beta levels that were similar to controls. The timing of measurement appears to be important, since elevated levels drop to normal within two days after the initiation of high dose chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/52\">",
"     52",
"    </a>",
"    ]. Whether these promising results can be generalized to autologous and stem cell transplants for other malignancies remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An aggressive, invasive diagnostic approach is usually justified early in the evaluation of pulmonary problems after autologous HCT. Infections are common but there are no sensitive noninvasive methods to diagnose opportunistic infections, and chest radiographs may be completely normal early in the disease. Although there are several glucocorticoid&ndash;responsive pulmonary processes to be considered, infectious causes must be excluded before starting systemic glucocorticoids.",
"   </p>",
"   <p>",
"    Patients with dyspnea and normal chest radiographs should undergo full pulmonary function testing with arterial blood gas analysis. A restrictive pattern or evidence of impaired gas exchange on pulmonary function testing should be followed by a chest high resolution computed tomography (HRCT) scan to look for subtle interstitial disease. HRCT of the chest is more sensitive than the plain chest radiograph and can be used as a guide for further diagnostic procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Echocardiography should be performed in patients with undiagnosed dyspnea to look for cardiac dysfunction.",
"   </p>",
"   <p>",
"    Bronchoscopy with bronchoalveolar lavage (BAL) should be performed in patients with diffuse pulmonary infiltrates. The additional diagnostic value of transbronchial biopsy in conjunction with BAL is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. A surgical lung biopsy should be strongly considered if a diagnosis is not made bronchoscopically. A diagnosis may alter management, although it is controversial whether outcome improves [",
"    <a class=\"abstract\" href=\"UTD.htm?14/25/14745/abstract/57\">",
"     57",
"    </a>",
"    ]. However, patients with focal infiltrates can often be given a trial of empiric antibiotics with or without antifungal agents, with bronchoscopy or other diagnostic procedure performed several days later if there is no response.",
"   </p>",
"   <p>",
"    Acute respiratory failure due to diffuse alveolar hemorrhage or acute pulmonary edema following autologous HCT often requires short term support with noninvasive ventilation or intubation with mechanical ventilation. Respiratory failure requiring prolonged mechanical ventilation is generally associated with a poor prognosis in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44598?source=see_link&amp;anchor=H5#H5\">",
"     \"Intensive care for oncology patients: Short-term prognosis\", section on 'Bone marrow transplantation'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/1\">",
"      Slavin MA, Meyers JD, Remington JS, Hackman RC. Toxoplasma gondii infection in marrow transplant recipients: a 20 year experience. Bone Marrow Transplant 1994; 13:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/2\">",
"      Geissmann F, Derouin F, Marolleau JP, et al. Disseminated toxoplasmosis following autologous bone marrow transplantation. Clin Infect Dis 1994; 19:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/3\">",
"      Miller RA, Daley J, Ghalie R, Kaizer H. Clonal analysis of T-cell deficiencies in autotransplant recipients. Blood 1991; 77:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/4\">",
"      Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2004; 170:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/5\">",
"      Afessa B, Abdulai RM, Kremers WK, et al. Risk factors and outcome of pulmonary complications after autologous hematopoietic stem cell transplant. Chest 2012; 141:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/6\">",
"      Todd K, Wiley F, Landaw E, et al. Survival outcome among 54 intubated pediatric bone marrow transplant patients. Crit Care Med 1994; 22:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/7\">",
"      Bojko T, Notterman DA, Greenwald BM, et al. Acute hypoxemic respiratory failure in children following bone marrow transplantation: an outcome and pathologic study. Crit Care Med 1995; 23:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/8\">",
"      Kuhlman JE, Fishman EK, Burch PA, et al. CT of invasive pulmonary aspergillosis. AJR Am J Roentgenol 1988; 150:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/9\">",
"      Mori M, Galvin JR, Barloon TJ, et al. Fungal pulmonary infections after bone marrow transplantation: evaluation with radiography and CT. Radiology 1991; 178:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/10\">",
"      Morrison VA, Haake RJ, Weisdorf DJ. The spectrum of non-Candida fungal infections following bone marrow transplantation. Medicine (Baltimore) 1993; 72:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/11\">",
"      Besnard M, Hartmann O, Valteau-Couanet D, et al. Systemic Candida infection in pediatric BM autotransplantation: clinical signs, outcome and prognosis. Bone Marrow Transplant 1993; 11:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/12\">",
"      Morrison VA, McGlave PB. Mucormycosis in the BMT population. Bone Marrow Transplant 1993; 11:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/13\">",
"      Rapoport AP, Rowe JM, Packman CH, Ginsberg SJ. Cardiac arrest after autologous marrow infusion. Bone Marrow Transplant 1991; 7:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/14\">",
"      Corso S, Vukelja SJ, Wiener D, Baker WJ. Diffuse alveolar hemorrhage following autologous bone marrow infusion. Bone Marrow Transplant 1993; 12:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/15\">",
"      Valteau D, Hartmann O, Brugieres L, et al. Streptococcal septicaemia following autologous bone marrow transplantation in children treated with high-dose chemotherapy. Bone Marrow Transplant 1991; 7:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/16\">",
"      Maiolino A, Biasoli I, Lima J, et al. Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria. Bone Marrow Transplant 2003; 31:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/17\">",
"      Schmid I, Stachel D, Pagel P, Albert MH. Incidence, predisposing factors, and outcome of engraftment syndrome in pediatric allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant 2008; 14:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/18\">",
"      Foncillas MA, Diaz MA, Sevilla J, et al. Engraftment syndrome emerges as the main cause of transplant-related mortality in pediatric patients receiving autologous peripheral blood progenitor cell transplantation. J Pediatr Hematol Oncol 2004; 26:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/19\">",
"      Carreras E, Fern&aacute;ndez-Avil&eacute;s F, Silva L, et al. Engraftment syndrome after auto-SCT: analysis of diagnostic criteria and risk factors in a large series from a single center. Bone Marrow Transplant 2010; 45:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/20\">",
"      Dispenzieri A, Lacy MQ, Hayman SR, et al. Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. Eur J Haematol 2008; 80:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/21\">",
"      Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/22\">",
"      Lopes da Silva R, Costa F, Ferreira G, de Sousa AB. Post-autologous hematopoietic SCT engraftment syndrome: a single center experience. Bone Marrow Transplant 2012; 47:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/23\">",
"      Doran HM, Sheppard MN, Collins PW, et al. Pathology of the lung in leukaemia and lymphoma: a study of 87 autopsies. Histopathology 1991; 18:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/24\">",
"      Clark JG, Hansen JA, Hertz MI, et al. NHLBI workshop summary. Idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis 1993; 147:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/25\">",
"      Robbins, RA, Linder, J, Stahl, MG, et al. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients (see comments). Am J Med 1989; 87:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/26\">",
"      Afessa B, Tefferi A, Litzow MR, Peters SG. Outcome of diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med 2002; 166:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/27\">",
"      Witte RJ, Gurney JW, Robbins RA, et al. Diffuse pulmonary alveolar hemorrhage after bone marrow transplantation: radiographic findings in 39 patients. AJR Am J Roentgenol 1991; 157:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/28\">",
"      Marasco WJ, Fishman EK, Kuhlman JE, Hruban RH. Acute pulmonary hemorrhage. CT evaluation. Clin Imaging 1993; 17:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/29\">",
"      Afessa B, Tefferi A, Litzow MR, et al. Diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med 2002; 166:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/30\">",
"      Jules-Elysee K, Stover DE, Yahalom J, et al. Pulmonary complications in lymphoma patients treated with high-dose therapy autologous bone marrow transplantation. Am Rev Respir Dis 1992; 146:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/31\">",
"      Grimwade DJ, Chopra R, King A, et al. Detection and significance of pulmonary Hodgkin's disease at autologous bone marrow transplantation. Bone Marrow Transplant 1994; 13:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/32\">",
"      Vaughan WP, Linder J, Robbins R, et al. Pulmonary surveillance using bronchoscopy and bronchoalveolar lavage during high-dose antineoplastic therapy. Chest 1991; 99:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/33\">",
"      Chao NJ, Duncan SR, Long GD, et al. Corticosteroid therapy for diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Ann Intern Med 1991; 114:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/34\">",
"      Metcalf JP, Rennard SI, Reed EC, et al. Corticosteroids as adjunctive therapy for diffuse alveolar hemorrhage associated with bone marrow transplantation. University of Nebraska Medical Center Bone Marrow Transplant Group. Am J Med 1994; 96:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/35\">",
"      Ip MS, Yuen KY, Chiu EK, et al. Pulmonary infections in bone marrow transplantation: the Hong Kong experience. Respiration 1995; 62:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/36\">",
"      Pecego R, Hill R, Appelbaum FR, et al. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation 1986; 42:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/37\">",
"      Carlson K, B&auml;cklund L, Smedmyr B, et al. Pulmonary function and complications subsequent to autologous bone marrow transplantation. Bone Marrow Transplant 1994; 14:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/38\">",
"      Badier M, Guillot C, Delpierre S, et al. Pulmonary function changes 100 days and one year after bone marrow transplantation. Bone Marrow Transplant 1993; 12:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/39\">",
"      Cerveri I, Zoia MC, Fulgoni P, et al. Late pulmonary sequelae after childhood bone marrow transplantation. Thorax 1999; 54:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/40\">",
"      Arvidson J, Bratteby LE, Carlson K, et al. Pulmonary function after autologous bone marrow transplantation in children. Bone Marrow Transplant 1994; 14:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/41\">",
"      Wilczynski SW, Erasmus JJ, Petros WP, et al. Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer. Am J Respir Crit Care Med 1998; 157:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/42\">",
"      Seiden, MV, Elias, A, Ayash, L, et al. Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimens. Bone Marrow Transplant 1992; 10:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/43\">",
"      Bhalla KS, Wilczynski SW, Abushamaa AM, et al. Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support. Am J Respir Crit Care Med 2000; 161:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/44\">",
"      Valteau D, Hartmann O, Benhamou E, et al. Nonbacterial nonfungal interstitial pneumonitis following autologous bone marrow transplantation in children treated with high-dose chemotherapy without total-body irradiation. Transplantation 1988; 45:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/45\">",
"      Wingard JR, Sostrin MB, Vriesendorp HM, et al. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation 1988; 46:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/46\">",
"      Gross TG, Hoge FJ, Jackson JD, et al. Fatal eosinophilic disease following autologous bone marrow transplantation. Bone Marrow Transplant 1994; 14:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/47\">",
"      Paz HL, Crilley P, Patchefsky A, et al. Bronchiolitis obliterans after autologous bone marrow transplantation. Chest 1992; 101:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/48\">",
"      Kalaycio M, Pohlman B, Kuczkowski E, et al. High-dose busulfan and the risk of pulmonary mortality after autologous stem cell transplant. Clin Transplant 2006; 20:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/49\">",
"      Ghalie R, Szidon JP, Thompson L, et al. Evaluation of pulmonary complications after bone marrow transplantation: the role of pretransplant pulmonary function tests. Bone Marrow Transplant 1992; 10:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/50\">",
"      Whittle AT, Davis M, Shovlin CL, et al. Alveolar macrophage activity and the pulmonary complications of haematopoietic stem cell transplantation. Thorax 2001; 56:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/51\">",
"      Anscher MS, Peters WP, Reisenbichler H, et al. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993; 328:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/52\">",
"      Murase T, Anscher MS, Petros WP, et al. Changes in plasma transforming growth factor beta in response to high-dose chemotherapy for stage II breast cancer: possible implications for the prevention of hepatic veno-occlusive disease and pulmonary drug toxicity. Bone Marrow Transplant 1995; 15:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/53\">",
"      Barloon TJ, Galvin JR, Mori M, et al. High-resolution ultrafast chest CT in the clinical management of febrile bone marrow transplant patients with normal or nonspecific chest roentgenograms. Chest 1991; 99:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/54\">",
"      Kuhlman JE. The role of chest CT in evaluation of the febrile bone marrow transplant recipient. Chest 1991; 99:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/55\">",
"      Patel NR, Lee PS, Kim JH, et al. The influence of diagnostic bronchoscopy on clinical outcomes comparing adult autologous and allogeneic bone marrow transplant patients. Chest 2005; 127:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/56\">",
"      Jain P, Sandur S, Meli Y, et al. Role of flexible bronchoscopy in immunocompromised patients with lung infiltrates. Chest 2004; 125:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/25/14745/abstract/57\">",
"      Hayes-Jordan A, Benaim E, Richardson S, et al. Open lung biopsy in pediatric bone marrow transplant patients. J Pediatr Surg 2002; 37:446.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4342 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-DE283444F4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_25_14745=[""].join("\n");
var outline_f14_25_14745=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNIQUE OF AUTOLOGOUS HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COMPARISON WITH ALLOGENEIC HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EARLY COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Respiratory infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37754268\">",
"      Aspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diffuse alveolar damage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15960344\">",
"      Engraftment syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Toxicity from chemotherapy and/or radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diffuse alveolar hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      LATE COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Respiratory infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Restrictive lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Bronchiolitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PREDICTING COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4342\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4342|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/18/23845\" title=\"diagnostic image 1\">",
"      Diffuse alveolar hemorrhage PA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4342|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/26/27048\" title=\"picture 1\">",
"      CMV pneumonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/4/30793\" title=\"picture 2\">",
"      Early DAD micrograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/11/41145\" title=\"picture 3\">",
"      Late DAD micrograph",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4871?source=related_link\">",
"      Acute respiratory distress syndrome: Prognosis and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37415?source=related_link\">",
"      Busulfan-induced pulmonary injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=related_link\">",
"      Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21990?source=related_link\">",
"      Cyclophosphamide pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=related_link\">",
"      Diagnosis of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44598?source=related_link\">",
"      Intensive care for oncology patients: Short-term prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=related_link\">",
"      Mucormycosis (zygomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28327?source=related_link\">",
"      Nitrosourea-induced pulmonary injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=related_link\">",
"      Overview of infections following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=related_link\">",
"      Prophylaxis of infections in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=related_link\">",
"      Pulmonary complications after allogeneic hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=related_link\">",
"      Radiation-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29306?source=related_link\">",
"      Supportive care after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=related_link\">",
"      The diffuse alveolar hemorrhage syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=related_link\">",
"      Therapeutic uses of recombinant coagulation factor VIIa",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_25_14746="Estradiol (systemic): Drug information";
var content_f14_25_14746=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Estradiol (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/58/38824?source=see_link\">",
"    see \"Estradiol (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/35/35383?source=see_link\">",
"    see \"Estradiol (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8018272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8018338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alora&reg;;",
"     </li>",
"     <li>",
"      Climara&reg;;",
"     </li>",
"     <li>",
"      Delestrogen&reg;;",
"     </li>",
"     <li>",
"      Depo&reg;-Estradiol;",
"     </li>",
"     <li>",
"      Divigel&reg;;",
"     </li>",
"     <li>",
"      Elestrin&reg;;",
"     </li>",
"     <li>",
"      Estrace&reg;;",
"     </li>",
"     <li>",
"      Estrasorb&reg;;",
"     </li>",
"     <li>",
"      EstroGel&reg;;",
"     </li>",
"     <li>",
"      Evamist&reg;;",
"     </li>",
"     <li>",
"      Femring&reg;;",
"     </li>",
"     <li>",
"      Femtrace&reg;;",
"     </li>",
"     <li>",
"      Menostar&reg;;",
"     </li>",
"     <li>",
"      Minivelle&trade;;",
"     </li>",
"     <li>",
"      Vivelle-Dot&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8018339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Climara&reg;;",
"     </li>",
"     <li>",
"      Depo&reg;-Estradiol;",
"     </li>",
"     <li>",
"      Estraderm&reg;;",
"     </li>",
"     <li>",
"      Estradot&reg;;",
"     </li>",
"     <li>",
"      EstroGel&reg;;",
"     </li>",
"     <li>",
"      Menostar&reg;;",
"     </li>",
"     <li>",
"      Oesclim&reg;;",
"     </li>",
"     <li>",
"      Sandoz-Estradiol Derm 100;",
"     </li>",
"     <li>",
"      Sandoz-Estradiol Derm 50;",
"     </li>",
"     <li>",
"      Sandoz-Estradiol Derm 75",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8090986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Estrogen Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8018394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     All dosage needs to be adjusted based upon the patient's response:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vulvar and vaginal atrophy associated with menopause:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M.:  Valerate",
"     </i>",
"     (Delestrogen&reg;): 10-20 mg every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intravaginal:",
"     </i>",
"     Vaginal ring (Femring&reg;): 0.05 mg intravaginally; following insertion, ring should remain in place for 3 months; dose may be increased to 0.1 mg if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral",
"     </i>",
"     (Estrace&reg;): 1-2 mg/day; administration should be cyclic (3 weeks on, 1 week off)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Topical gel",
"     </i>",
"     (EstroGel&reg;): 1.25 g/day applied at the same time each day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Transdermal",
"     </i>",
"     (Alora&reg;, Climara&reg;, Estraderm&reg;, Vivelle-Dot&reg;): Refer to product-specific dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer, metastatic (appropriately selected patients):",
"     </b>",
"     Oral (Estrace&reg;): Males and postmenopausal females: 10 mg 3 times/day",
"     <b>",
"      or",
"     </b>",
"     (unlabeled dosing) postmenopausal women: 2 mg 3 times/day (Ellis, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypoestrogenism (female) due to hypogonadism, castration, or primary ovarian failure:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral",
"     </i>",
"     (Estrace&reg;): 1-2 mg/day; titrate as necessary to control symptoms using minimal effective dose for maintenance therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M: Valerate",
"     </i>",
"     (Delestrogen&reg;): 10-20 mg every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Transdermal",
"     </i>",
"     (Alora&reg;, Climara&reg;, Estraderm&reg;, Vivelle-Dot&reg;): Refer to product-specific dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypoestrogenism (female) due to hypogonadism:",
"     </b>",
"     <i>",
"      I.M: Cypionate",
"     </i>",
"     (Depo&reg;-Estradiol): 1.5-2 mg monthly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteoporosis prevention (females):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral",
"     </i>",
"     (Estrace&reg;): Lowest effective dose has not been determined; doses of 0.5 mg/day in a cyclic regimen for 23 days of a 28-week cycle were used in clinical studies",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Transdermal",
"     </i>",
"     (Alora&reg;, Climara&reg;, Estraderm&reg;, Menostar&reg;, Vivelle-Dot&reg;): Refer to product-specific dosing (below)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prostate cancer, advanced (androgen-dependent):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M.: Valerate",
"     </i>",
"     (Delestrogen&reg;): 30 mg or more every 1-2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral",
"     </i>",
"     (Estrace&reg;): 1-2 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vasomotor symptoms associated with menopause:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Estrace&reg;: 1-2 mg daily, adjusted as necessary to limit symptoms; administration should be cyclic (3 weeks on, 1 week off)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Femtrace&reg;: Initial dose: 0.45 mg/day; dosage range 0.45-1.8 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M. Cypionate",
"     </i>",
"     (Depo&reg;-Estradiol): 1-5 mg every 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M. Valerate",
"     </i>",
"     (Delestrogen&reg;): 10-20 mg every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Topical emulsion",
"     </i>",
"     (Estrasorb&reg;): 3.48 g applied once daily in the morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Topical gel:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Divigel&reg;: 0.25 g/day; adjust dose based on patient response. Dosing range: 0.25-1 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Elestrin&reg;: 0.87 g/day applied at the same time each day; adjust dose based on patient response. Dosing range: 0.87-1.7 g/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     EstroGel&reg;: 1.25 g/day applied at the same time each day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Topical spray",
"     </i>",
"     (Evamist&reg;): Initial: One spray (1.53 mg) per day. Adjust dose based on patient response. Dosing range: 1-3 sprays per day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Transdermal",
"     </i>",
"     (Alora&reg;, Climara&reg;, Estraderm&reg;, Minivelle&trade;, Vivelle-Dot&reg;): See product-specific dosing (below)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Vaginal ring",
"     </i>",
"     (Femring&reg;): Initial: 0.05 mg intravaginally; following insertion, ring should remain in place for 3 months; dose may be increased to 0.1 mg if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Transdermal product-specific dosing:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Indicated dose may be used continuously in patients without an intact uterus. Some product labeling states they may be given continuously or cyclically (3 weeks on, 1 week off) in patients with an intact uterus",
"     <b>",
"      (exception - Menostar&reg;, see specific dosing instructions).",
"     </b>",
"     When changing patients from oral to transdermal therapy, start transdermal patch 1 week after discontinuing oral hormone (may begin sooner if symptoms reappear within 1 week):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Transdermal once-weekly patch:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Vasomotor symptoms associated with menopause, vulvar and vaginal atrophy associated with menopause, female hypoestrogenism (due to hypogonadism, castration, or primary ovarian failure):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Climara&reg;: Initial: Apply 0.025 mg/day patch once weekly. Adjust dose as necessary to control symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prevention of osteoporosis in postmenopausal women:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Climara&reg;: Apply patch once weekly; minimum effective dose 0.025 mg/day; adjust dosage based on response to therapy as indicated by biological markers and bone mineral density.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Menostar&reg;: Apply patch once weekly (0.014 mg/day). In women with a uterus, also administer a progestin for 14 days every 6-12 months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Transdermal twice-weekly patch:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Vasomotor symptoms associated with menopause, vulvar and vaginal atrophy associated with menopause, female  hypoestrogenism (due to hypogonadism, castration, or primary ovarian failure): Titrate to lowest dose possible to control symptoms, adjusting initial dose after the first month of therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Alora&reg;, Estraderm&reg;: Apply 0.05 mg patch twice weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Vivelle-Dot&reg;: Apply 0.0375 mg patch twice weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Vasomotor symptoms associated with menopause: Titrate to lowest dose possible to control symptoms, adjusting initial dose after the first month of therapy: Minivelle&trade;: Apply 0.0375 mg patch twice weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prevention of osteoporosis in postmenopausal women:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Alora&reg;, Vivelle-Dot&reg;: Apply 0.025 mg patch twice weekly; increase dose as necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Estraderm&reg;: Apply 0.05 mg patch twice weekly; increase dose as necessary",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8018395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8018425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Emulsion, topical, as hemihydrate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Estrasorb&reg;: 2.5 mg/g (56s) [contains ethanol, soybean oil; each pouch contains estradiol hemihydrate 4.35 mg; contents of two pouches delivers estradiol 0.05 mg/day]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Divigel&reg;: 0.1% (30s) [contains ethanol; delivers estradiol 0.25 mg/0.25 g packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Divigel&reg;: 0.1% (30s) [contains ethanol; delivers estradiol 0.5 mg/0.5 g packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Divigel&reg;: 0.1% (30s) [contains ethanol; delivers estradiol 1 mg/1 g packet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elestrin&reg;: 0.06% (35 g [DSC]) [contains ethanol; delivers estradiol 0.52 mg/0.87 g; 30 actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elestrin&reg;: 0.06% (70 g) [contains ethanol; delivers estradiol 0.52 mg/0.87 g; 60 actuations; packaged as 2x35 g]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     EstroGel&reg;: 0.06% (50 g) [contains ethanol; delivers estradiol 0.75 mg/1.25 g; 32 actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, oil, as cypionate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depo&reg;-Estradiol: 5 mg/mL (5 mL) [contains chlorobutanol, cottonseed oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, oil, as valerate: 10 mg/mL (5 mL); 20 mg/mL (5 mL); 40 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Delestrogen&reg;: 10 mg/mL (5 mL) [contains chlorobutanol, sesame oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Delestrogen&reg;: 20 mg/mL (5 mL); 40 mg/mL (5 mL) [contains benzyl alcohol, benzyl benzoate, castor oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal [once-weekly patch]: 0.025 mg/24 hours (4s); 0.0375 mg/24 hours (4s); 0.05 mg/24 hours (4s); 0.06 mg/24 hours (4s); 0.075 mg/24 hours (4s); 0.1 mg/24 hours (4s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Climara&reg;: 0.025 mg/24 hours (4s) [6.5 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 2 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Climara&reg;: 0.0375 mg/24 hours (4s) [9.375 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 2.85 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Climara&reg;: 0.05 mg/24 hours (4s) [12.5 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 3.8 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Climara&reg;: 0.06 mg/24 hours (4s) [15 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 4.55 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Climara&reg;: 0.075 mg/24 hours (4s) [18.75 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 5.7 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Climara&reg;: 0.1 mg/24 hours (4s) [25 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 7.6 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Menostar&reg;: 0.014 mg/24 hours (4s) [3.25 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 1 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal [twice-weekly patch]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alora&reg;: 0.025 mg/24 hours (8s) [9 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 0.77 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alora&reg;: 0.05 mg/24 hours (8s) [18 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 1.5 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alora&reg;: 0.075 mg/24 hours (8s) [27 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 2.3 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alora&reg;: 0.1 mg/24 hours (8s) [36 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 3.1 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minivelle&trade;: 0.037 mg/24 hours (8s) [2.48 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; total estradiol 0.62 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minivelle&trade;: 0.05 mg/24 hours (8s) [3.3 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; total estradiol 0.83 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minivelle&trade;: 0.075 mg/24 hours (8s) [4.95 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; total estradiol 1.24 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minivelle&trade;: 0.1 mg/24 hours (8s) [6.6 cm",
"     <sup>",
"      2",
"     </sup>",
"     ; total estradiol 1.65 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vivelle-Dot&reg;: 0.025 mg/24 hours (24s) [2.5 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 0.39 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vivelle-Dot&reg;: 0.0375 mg/24 hours (24s) [3.75 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 0.585 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vivelle-Dot&reg;: 0.05 mg/24 hours (24s) [5 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 0.78 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vivelle-Dot&reg;: 0.075 mg/24 hours (24s) [7.5 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 1.17 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vivelle-Dot&reg;: 0.1 mg/24 hours (24s) [10 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total estradiol 1.56 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ring, vaginal, as acetate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Femring&reg;: 0.05 mg/24 hours (1s) [total estradiol 12.4 mg; releases 0.05 mg/24 hours over 3 months]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Femring&reg;: 0.1 mg/24 hours (1s) [total estradiol 24.8 mg; releases 0.1 mg/24 hours over 3 months]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Evamist&reg;: 1.53 mg/spray (8.1 mL) [contains ethanol; delivers 75 sprays after priming]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [micronized]: 0.5 mg, 1 mg, 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Estrace&reg;: 0.5 mg, 1 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Estrace&reg;: 2 mg [scored; contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as acetate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Femtrace&reg;: 0.45 mg [DSC], 0.9 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8018341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Oral tablet, patch, valerate oil for injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8018398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The use of a progestin should be considered when administering estrogens to postmenopausal women with an intact uterus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection formulation: Intramuscular use only. Estradiol valerate should be injected into the upper outer quadrant of the gluteal muscle; administer with a dry needle (solution may become cloudy with wet needle).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Emulsion (Estrasorb&reg;): Apply to clean, dry skin while in a sitting position. Contents of two pouches (total 3.48 g) are to be applied individually, once daily in the morning. Apply contents of first pouch to left thigh; massage into skin of left thigh and calf until thoroughly absorbed (~3 minutes). Apply excess from both hands to the buttocks. Apply contents of second pouch to the right thigh; massage into skin of right thigh and calf until thoroughly absorbed (~3 minutes). Apply excess from both hands to buttocks. Wash hands with soap and water. Allow skin to dry before covering legs with clothing. Do not apply to other areas of body. Do not apply to red or irritated skin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel: Apply to clean, dry, unbroken skin at the same time each day. Allow to dry for 5 minutes prior to dressing. Gel is flammable; avoid fire or flame until dry. After application, wash hands with soap and water. Prior to the first use, pump must be primed. Do not apply gel to breast.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Divigel&reg;: Apply entire contents of packet to right or left upper thigh each day (alternate sites). Do not apply to face, breasts, vaginal area or irritated skin. Apply over an area ~5x7 inches. Do not wash application site for 1 hour. Allow gel to dry before dressing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elestrin&reg;: Apply to upper arm and shoulder area using two fingers to spread gel. Apply after bath or shower; allow at least 2 hours between applying gel and going swimming. Wait at least 25 minutes before applying sunscreen to application area. Do not apply sunscreen to application area for &ge;7 days (may increase absorption of gel).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     EstroGel&reg;: Apply gel to the arm, from the wrist to the shoulder. Spread gel as thinly as possible over one arm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Spray: Evamist&reg;: Prior to first use, prime pump by spraying 3 sprays with the cover on. To administer dose, hold container upright and vertical and rest the plastic cone flat against the skin while spraying. Spray to the inner surface of the forearm, starting near the elbow. If more than one spray is needed, apply to adjacent but not overlapping areas. Apply at the same time each day. Allow spray to dry for ~2 minutes; do not rub into skin; do not cover with clothing until dry. Do not wash application site for at least 60 minutes. Apply to clean, dry, unbroken skin. Do not apply to skin other than that of the forearm. Make sure that children do not come in contact with any skin area where the drug was applied. If contact with children is unavoidable, wear a garment with long sleeves that covers the site of application. If direct exposure should occur, wash the child in the area of exposure with soap and water as soon as possible.  Solution contained in the spray is flammable; avoid fire, flame, or smoking until spray has dried. If needed, sunscreen should be applied ~1 hour prior to application of Evamist&reg;.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transdermal patch: Do not apply transdermal system to breasts, but place on trunk of body (preferably abdomen). Rotate application sites allowing a 1-week interval between applications at a particular site. Do not apply to oily, damaged or irritated skin; avoid waistline or other areas where tight clothing may rub the patch off. Apply patch immediately after removing from protective pouch. In general, if patch falls off, the same patch may be reapplied or a new system may be used for the remainder of the dosing interval (not recommended with all products). When replacing patch, reapply to a new site. Swimming, bathing or showering are not expected to affect use of the patch. Note the following exceptions:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Estraderm&reg;: Do not apply to an area exposed to direct sunlight.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Climara&reg;, Menostar&reg;, Minivelle&trade;: Swimming, bathing, or wearing patch while in a sauna have not been studied; adhesion of patch may be decreased or delivery of estradiol may be affected. Showering is not expected to cause the Minivelle&trade; patch to fall off. Remove patch slowly after use to avoid skin irritation. If any adhesive remains on the skin after removal, first allow skin to dry for 15 minutes, then gently rub area with an oil-based cream or lotion. If patch falls off, a new patch should be applied for the remainder of the dosing interval.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vaginal ring: Exact positioning is not critical for efficacy; however, patient should not feel anything once inserted. In case of discomfort, ring should be pushed further into vagina. If ring is expelled prior to 90 days, it may be rinsed off and reinserted. Ensure proper vaginal placement of the ring to avoid inadvertent urinary bladder insertion. If vaginal infection develops, Femring&reg; may remain in place during local treatment of a vaginal infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8018342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of moderate-to-severe vasomotor symptoms associated with menopause; treatment of moderate-to-severe vulvar and vaginal atrophy associated with menopause; hypoestrogenism (due to hypogonadism, castration, or primary ovarian failure); advanced prostatic cancer (palliation); metastatic breast cancer (palliation) in men and postmenopausal women; postmenopausal osteoporosis (prophylaxis)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8018336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Alora&reg; may be confused with Aldara&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Elestrin&reg; may be confused with alosetron",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high [oral and transdermal patch]; Strength of recommendation - strong [oral and transdermal patch]).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vivelle: Brand name for estradiol [U.S. and multiple international markets, but also the brand name for ethinyl estradiol and norgestimate [Austria]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8018352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined. Some adverse reactions observed with estrogen and/or progestin combination therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, DVT, edema, hypertension, MI, stroke, syncope, TIA, vasodilation,  venous thromboembolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, dementia, dizziness, epilepsy exacerbation, headache, insomnia, irritability, mental depression, migraine, mood disturbances, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, chloasma, dermatitis, erythema multiforme, erythema nodosum, hemorrhagic eruption, hirsutism, loss of scalp hair, melasma, rash, pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast cancer, breast enlargement, breast pain, breast tenderness, carbohydrate intolerance, fibrocystic breast changes, fluid retention, galactorrhea, hot flashes, hypocalcemia, libido changes, nipple discharge, nipple pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, abdominal pain, bloating, cholecystitis, cholelithiasis, constipation, diarrhea, dyspepsia, flatulence, gallbladder disease, gastritis, nausea, pancreatitis, vomiting, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Alterations in frequency and flow of bleeding patterns, breakthrough bleeding, cervical ectropion changes, cervical secretion changes, cystitis, dysmenorrhea, endometrial cancer, endometrial hyperplasia, genital eruption, menorrhagia, metrorrhagia, ovarian cancer, ovarian cyst, Pap smear suspicious, spotting, uterine leiomyomata size increased, leukorrhea, uterine cancer, uterine enlargement, uterine pain, urinary incontinence, urogenital pruritus, vaginal candidiasis, vaginal discharge, vaginal moniliasis, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Aggravation of porphyria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, hepatic hemangioma enlargement",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gel, spray: Application site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal patches: Erythema, irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, chorea, leg cramps, myalgia, muscle cramps, skeletal pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blindness, contact lens intolerance, corneal curvature steepening, retinal vascular thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma exacerbation, pulmonary thromboembolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid/anaphylactic reactions, hypersensitivity reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Postmarketing and/or case reports: Vaginal ring: Bowel obstruction, ring adherence to vaginal wall, toxic shock syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8018348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Angioedema or anaphylactic reaction to estradiol or any component of the formulation; undiagnosed abnormal vaginal bleeding; DVT or PE (current or history of); active or history of arterial thromboembolic disease (eg, stroke, MI); carcinoma of the breast (known, suspected or history of), except in appropriately selected patients being treated for metastatic disease; estrogen-dependent tumor; hepatic dysfunction or disease; known protein C, protein S, antithrombin deficiency or other known thrombophilic disorders; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8018349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer:",
"     <b>",
"      [U.S. Boxed Warning]: Based on data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in postmenopausal women using conjugated estrogens (CE) in combination with medroxyprogesterone acetate (MPA).",
"     </b>",
"     This risk may be associated with duration of use and declines once combined therapy is discontinued (Chlebowski, 2009). The risk of invasive breast cancer was decreased in postmenopausal women with a hysterectomy using CE only, regardless of weight. However, the risk was not significantly decreased in women at high risk for breast cancer (family history of breast cancer, personal history of benign breast disease) (Anderson, 2012). An increase in abnormal mammogram findings has also been reported with estrogen alone or in combination with progestin therapy. Estrogen use may lead to severe hypercalcemia in patients with breast cancer and bone metastases; discontinue estrogen if hypercalcemia occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent dementia. In the Women&rsquo;s Health Initiative Memory Study (WHIMS), an increased incidence of dementia was observed in women &ge;65 years of age taking CE alone or in combination with MPA.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endometrial carcinoma:",
"     <b>",
"      [U.S. Boxed Warning]: The use of unopposed estrogen in women with an intact uterus is associated with an increased risk of endometrial cancer. The addition of a progestin to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer.",
"     </b>",
"     The use of a progestin is not generally required when low doses of estrogen are used locally for vaginal atrophy (NAMS, 2012).",
"     <b>",
"      Adequate diagnostic measures, including endometrial sampling if indicated, should be performed to rule out malignancy in postmenopausal women with undiagnosed abnormal vaginal bleeding.",
"     </b>",
"     Estrogens may exacerbate endometriosis. Malignant transformation of residual endometrial implants has been reported posthysterectomy with unopposed estrogen therapy. Consider adding a progestin in women with residual endometriosis posthysterectomy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inherited thrombophilia: Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho, 2010; van Vlijmen 2011). Use is contraindicated in women with protein C, protein S, antithrombin deficiency, or other known thrombophilic disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased; use with caution in patients with familial defects of lipoprotein metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian cancer: Postmenopausal estrogen therapy and combined estrogen/progesterone therapy may increase the risk of ovarian cancer; however, the absolute risk to an individual woman is small. Although results from various studies are not consistent, risk does not appear to be significantly associated with the duration, route, or dose of therapy. In one study, the risk decreased after 2 years following discontinuation of therapy (M&oslash;rch, 2009). Although the risk of ovarian cancer is rare, women who are at an increased risk (eg, family history) should be counseled about the association (NAMS, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia, or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use caution in patients with asthma; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent coronary heart disease.",
"     </b>",
"     Using data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of deep vein thrombosis (DVT) and stroke has been reported with CE and an increased risk of DVT, stroke, pulmonary emboli (PE) and myocardial infarction (MI) has been reported with CE with MPA in postmenopausal women. Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of venous thromboembolism (VTE). Adverse cardiovascular events have also been reported in males taking estrogens for prostate cancer. Risk factors should be managed appropriately; discontinue use if adverse cardiovascular events occur or are suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including cardiac or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Epilepsy: Use caution with epilepsy; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: Use of postmenopausal estrogen may be associated with an increased risk of gallbladder disease requiring surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic dysfunction: Estrogens are poorly metabolized in patients with hepatic dysfunction. Use caution with a history of cholestatic jaundice associated with prior estrogen use or pregnancy. Discontinue if jaundice develops or if acute or chronic hepatic disturbances occur. Use is contraindicated with hepatic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic hemangiomas: Use with caution in patients with hepatic hemangiomas; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hereditary angioedema: Exogenous estrogens may exacerbate angioedema symptoms in women with hereditary angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypocalcemia: Use with caution in patients with severe hypocalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Migraine: Use caution with migraine; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use with caution in patients with porphyria; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SLE: Use with caution in patients with SLE; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid oral and transdermal patch estrogen products (with or without progestins) in this age group due to potential of increased risk of breast and endometrial cancers, and lack of proven cardioprotection and cognitive protection (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Prior to puberty, estrogens may cause premature closure of the epiphyses, premature breast development in girls or gynecomastia in boys. Vaginal bleeding and vaginal cornification may also be induced in girls.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, estrogens should be discontinued at least 4-6 weeks prior to elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chlorobutanol: Some products may contain chlorobutanol (a chloral derivative) as a preservative, which may be habit forming.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tartrazine: Some products may contain tartrazine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topical emulsion, gel: Absorption of the topical emulsion (Estrasorb&reg;) and topical gel (Elestrin&reg;) is increased by application of sunscreen; do not apply sunscreen within close proximity of estradiol. Application of Divigel&reg; or EstroGel&reg; with sunscreen has not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topical spray: When sunscreen is applied ~1 hour prior to the topical spray (Evamist&reg;), no change in absorption was observed (estradiol absorption was decreased when sunscreen is applied 1 hour after Evamist&reg;).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Transdermal patch: May contain conducting metal (eg, aluminum); remove patch prior to MRI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaginal ring: Use may not be appropriate in women with narrow vagina, vaginal stenosis, vaginal infections, cervical prolapse, rectoceles, cystoceles, or other conditions which may increase the risk of vaginal irritation, ulceration, or increase the risk of expulsion. Ring should be removed in case of ulceration, erosion, or adherence to vaginal wall; do not reinsert until healing is complete. Ensure proper vaginal placement of the ring to avoid inadvertent urinary bladder insertion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis use: For use only in women at significant risk of osteoporosis and for who other nonestrogen medications are not considered appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Risks vs benefits:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should be used for the shortest duration possible at the lowest effective dose consistent with treatment goals.",
"     </b>",
"     Before prescribing estrogen therapy to postmenopausal women, the risks and benefits must be weighed for each patient. Women should be informed of these risks and benefits, as well as possible effects of progestin when added to estrogen therapy. Patients should be reevaluated as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from Women&rsquo;s Health Initiative (WHI) studies, which evaluated oral CE 0.625 mg with or without MPA 2.5 mg relative to placebo in postmenopausal women. Other combinations and dosage forms of estrogens and progestins were not studied.",
"     <b>",
"      Outcomes reported from clinical trials using CE with or without MPA should be assumed to be similar for other doses and other dosage forms of estrogens and progestins until comparable data becomes available.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary exposure: Estradiol may be transferred to another person following skin-to-skin contact with the application site.",
"     <b>",
"      [U.S. Boxed Warning]: Breast budding and breast masses in prepubertal females and gynecomastia and breast masses in prepubertal males have been reported following unintentional contact with application sites of women using topical estradiol (Evamist&reg;). Patients should strictly adhere to instructions for use in order to prevent secondary exposure. In most cases, conditions resolved with removal of estradiol exposure.",
"     </b>",
"     If unexpected changes in sexual development occur in prepubertal children, the possibility of unintentional estradiol exposure should be evaluated by a healthcare provider. Discontinue if conditions for the safe use of the topical spray cannot be met.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vulvar and vaginal atrophy use: Moderate-to-severe symptoms of vulvar and vaginal atrophy include vaginal dryness, dyspareunia, and atrophic vaginitis. When used solely for the treatment of vulvar and vaginal atrophy, topical vaginal products should be considered. Use caution applying topical products to severely atrophic vaginal mucosa. Use of a progestin is normally not required when low-dose estrogen is applied locally and only for this purpose (NAMS, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8018356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2A6 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C8 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8018357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women.  Management: Monitor for reduced growth hormone efficacy. A larger somatropin dose may be required to reach treatment goal.  This interaction does not appear to apply to non-orally administered estrogens (e.g., transdermal, vaginal ring).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F8018361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (routine use increases estrogen level and risk of breast cancer). Ethanol may also increase the risk of osteoporosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Folic acid absorption may be decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease levels. Herbs with estrogenic properties may enhance the adverse/toxic effect of estrogen derivatives; examples include alfalfa, black cohosh, bloodroot, hops, kudzu, licorice, red clover, saw palmetto, soybean, thyme, wild yam, yucca.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8018343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8018344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In general, the use of estrogen and progestin as in combination hormonal contraceptives has not been associated with teratogenic effects when inadvertently taken early in pregnancy. These products are contraindicated for use during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8018346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8018347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Estrogens are excreted in breast milk and have been shown to decrease the quantity and quality of human milk. The manufacturer recommends that caution be used if administered to breast-feeding women. Monitor the growth of the infant closely.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F8018397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ensure adequate calcium and vitamin D intake when used for the prevention of osteoporosis.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8018427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Emulsion",
"     </b>",
"     (Estrasorb Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4.35 mg/1.74 g (1.74 g): $1.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Divigel Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg/0.25gm (1): $3.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg/0.5 g (1): $3.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/g (1 g): $3.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Elestrin Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.52 MG/0.87 GM (0.06%) (26 g): $89.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Estrogel Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.75 MG/1.25 GM (0.06%) (50 g): $93.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oil",
"     </b>",
"     (Delestrogen Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (5 mL): $113.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (5 mL): $160.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/mL (5 mL): $265.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oil",
"     </b>",
"     (Depo-Estradiol Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/mL (5 mL): $46.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oil",
"     </b>",
"     (Estradiol Valerate Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (5 mL): $95.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (5 mL): $134.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/mL (5 mL): $223.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch weekly",
"     </b>",
"     (Climara Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025 mg/24 hrs (4): $103.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.0375 mg/24 hrs (4): $103.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05 mg/24 hrs (1): $25.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.06 mg/24 hrs (4): $103.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.075 mg/24 hrs (4): $103.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg/24 hrs (1): $25.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch weekly",
"     </b>",
"     (Estradiol Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025 mg/24 hrs (4): $60.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.0375 mg/24 hrs (4): $60.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05 mg/24 hrs (4): $60.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.06 mg/24 hrs (4): $60.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.075 mg/24 hrs (4): $60.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg/24 hrs (4): $60.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch weekly",
"     </b>",
"     (Menostar Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14 mcg/24 hrs (4): $110.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch, twice-weekly",
"     </b>",
"     (Alora Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025 mg/24 hrs (1): $8.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05 mg/24 hrs (1): $9.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.075 mg/24 hrs (1): $9.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg/24 hrs (1): $10.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch, twice-weekly",
"     </b>",
"     (Minivelle Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.0375 mg/24 hrs (8): $83.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05 mg/24 hrs (8): $83.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.075 mg/24 hrs (8): $83.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg/24 hrs (8): $83.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch, twice-weekly",
"     </b>",
"     (Vivelle-Dot Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.025 mg/24 hrs (8): $83.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.0375 mg/24 hrs (8): $83.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05 mg/24 hrs (8): $83.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.075 mg/24 hrs (8): $83.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg/24 hrs (8): $83.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ring",
"     </b>",
"     (Femring Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05 mg/24 hrs (1): $235.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg/24 hrs (1): $250.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Evamist Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.53 mg/spray (8.1 mL): $100.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Estrace Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (100): $278.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $278.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $357.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Estradiol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg (100): $28.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $35.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $49.55",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8018403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Routine physical examination that includes blood pressure and Papanicolaou smear, breast exam, mammogram. Monitor for signs of endometrial cancer in female patients with uterus. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding. Monitor for loss of vision, sudden onset of proptosis, diplopia, migraine; signs and symptoms of thromboembolic disorders; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias; thyroid function in patients on thyroid hormone replacement therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Menostar&reg;:  When used in a woman with a uterus, endometrial sampling is recommended at yearly intervals or when clinically indicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Menopausal symptoms, vulvar and vaginal atrophy: Assess need for therapy at 3- to 6-month intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevention of osteoporosis: Bone density measurement",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F8018384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6 months to 10 years: &lt;15 pg/mL (SI: &lt;55 pmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Males: 10-50 pg/mL (SI: 37-184 pmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Females:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premenopausal: 30-400 pg/mL (SI: 110-1468 pmol/L) (depending on phase of menstrual cycle)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Postmenopausal: 0-30 pg/mL (SI: 0-110 pmol/L)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F11390228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aerodiol (AT, BE);",
"     </li>",
"     <li>",
"      Bedol (GB, IE);",
"     </li>",
"     <li>",
"      Climaderm (BR, VE);",
"     </li>",
"     <li>",
"      Climara (AT, AU, BE, BG, CH, CL, CZ, EE, FI, FR, IE, KP, NZ, PH, PL, RU, TH, ZA);",
"     </li>",
"     <li>",
"      Dermestril (BE, CL, CZ, DE, FI, IT, PT);",
"     </li>",
"     <li>",
"      Dermestril Septem (FR);",
"     </li>",
"     <li>",
"      Divigel (CH, DK, EE, IN, MY, SE, SG, TH, TW);",
"     </li>",
"     <li>",
"      Enadiol (CN);",
"     </li>",
"     <li>",
"      Estra Gel (TW);",
"     </li>",
"     <li>",
"      Estrade (TW);",
"     </li>",
"     <li>",
"      Estraderm (AU, CO, DK, SE);",
"     </li>",
"     <li>",
"      Estraderm MX (AU, IN, PT, SG);",
"     </li>",
"     <li>",
"      Estraderm TTS (AE, AT, BF, BH, BJ, CI, CO, CY, CZ, DE, EG, ET, FR, GB, GH, GM, GN, GR, IL, IQ, IR, IT, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NZ, OM, PL, PY, QA, SA, SC, SD, SL, SN, SY, TN, TR, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Estradot (AU, BR, CZ, DE, FI, GB, GR, IE, NO, PT, SE, UY);",
"     </li>",
"     <li>",
"      Estrapatch (FR);",
"     </li>",
"     <li>",
"      Estreva (CN, DE, HK, PE, PT, TR);",
"     </li>",
"     <li>",
"      Estreva Gel (PE);",
"     </li>",
"     <li>",
"      Estrifam (DE);",
"     </li>",
"     <li>",
"      Estro-Pause (ZA);",
"     </li>",
"     <li>",
"      Estrofem (AR, AT, AU, BE, BR, CH, CL, CZ, DK, EE, FI, FR, HK, IL, IN, NZ, PH, RU, SG, TH, UY);",
"     </li>",
"     <li>",
"      Estrofem Forte (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Estrogel (VE);",
"     </li>",
"     <li>",
"      Estronorm (NO);",
"     </li>",
"     <li>",
"      Evorel (AR, BB, BM, BS, DK, GY, IE, IL, JM, NL, NO, PR, SE, SR, TT, UY, ZA);",
"     </li>",
"     <li>",
"      Evorel Conti (BB, BM, BS, GY, JM, NL, PR, SR, TT);",
"     </li>",
"     <li>",
"      Fem 7 (CL);",
"     </li>",
"     <li>",
"      Femanest (SE);",
"     </li>",
"     <li>",
"      Fematrix (GB, IE);",
"     </li>",
"     <li>",
"      Feminova (BE);",
"     </li>",
"     <li>",
"      Femsept (FR);",
"     </li>",
"     <li>",
"      Femseven (GB, IE);",
"     </li>",
"     <li>",
"      Femtran (AU, NZ);",
"     </li>",
"     <li>",
"      Ginoderm Gel (PY);",
"     </li>",
"     <li>",
"      Gynokadin (DE);",
"     </li>",
"     <li>",
"      GynPolar (DE);",
"     </li>",
"     <li>",
"      Kliovance (AU);",
"     </li>",
"     <li>",
"      Lindisc (AR, CO, CR, EC, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Linoladiol N (EE);",
"     </li>",
"     <li>",
"      Lumelin 2 (TW);",
"     </li>",
"     <li>",
"      Menodin-Retard (CO);",
"     </li>",
"     <li>",
"      Menorest (AU, DE, IT);",
"     </li>",
"     <li>",
"      Merimono (DE);",
"     </li>",
"     <li>",
"      Oesclim (FR);",
"     </li>",
"     <li>",
"      Oestrodose (IL);",
"     </li>",
"     <li>",
"      Oestrogel (CL);",
"     </li>",
"     <li>",
"      Postmenop (TH);",
"     </li>",
"     <li>",
"      Primogyn Depot (ZA);",
"     </li>",
"     <li>",
"      Progynon (CH, DE, DK, IT, SE);",
"     </li>",
"     <li>",
"      Progynon Depot (IN, TW);",
"     </li>",
"     <li>",
"      Progynova (AR, AT, AU, BE, BZ, CL, CN, CO, CR, DO, FI, FR, GT, HN, ID, IL, IN, KP, MY, NI, NO, NZ, PA, PE, PH, PL, RU, SE, SG, SV, UY, VE, ZA);",
"     </li>",
"     <li>",
"      Prosu 2 (TW);",
"     </li>",
"     <li>",
"      Provames (FR);",
"     </li>",
"     <li>",
"      Sandrena (BR, CH, CN);",
"     </li>",
"     <li>",
"      Sandrena Gel (AU, DE);",
"     </li>",
"     <li>",
"      Sisare Gel (DE);",
"     </li>",
"     <li>",
"      Thais (FR);",
"     </li>",
"     <li>",
"      Tradelia (DE);",
"     </li>",
"     <li>",
"      Vivelle-Dot (BE, DK);",
"     </li>",
"     <li>",
"      Vivelledot (FR);",
"     </li>",
"     <li>",
"      Zumenon (AT, BE, GB)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8018378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Estrogens are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estradiol is the principle intracellular human estrogen and is more potent than estrone and estriol at the receptor level; it is the primary estrogen secreted prior to menopause. Following menopause, estrone and estrone sulfate are more highly produced. Estrogens modulate the pituitary secretion of gonadotropins, luteinizing hormone, and follicle-stimulating hormone through a negative feedback system; estrogen replacement reduces elevated levels of these hormones in postmenopausal women.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8018385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed from the gastrointestinal tract, mucous membranes, and the skin. Average serum estradiol concentrations (C",
"     <sub>",
"      avg",
"     </sub>",
"     ) vary by product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Femtrace&reg;: C",
"     <sub>",
"      avg",
"     </sub>",
"     : 23.5-92.1 pg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Injection: Estradiol valerate and estradiol cypionate are absorbed over several weeks following I.M. injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Alora&reg;: C",
"     <sub>",
"      avg",
"     </sub>",
"     : 41-98 pg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Climara&reg;: C",
"     <sub>",
"      avg",
"     </sub>",
"     : 22-106 pg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Divigel&reg;: C",
"     <sub>",
"      avg",
"     </sub>",
"     : 9.8-30.5 pg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Elestrin&reg;: C",
"     <sub>",
"      avg",
"     </sub>",
"     : 15.4-39.2 pg/mL; Exposure increased by 55% with application of sunscreen 10 minutes prior to dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Estraderm&reg; 0.1 mg/day: C",
"     <sub>",
"      avg",
"     </sub>",
"     : 73 pg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Estrasorb&reg;: Mean serum concentration on day 22 of therapy: ~35-65 pg/mL; Exposure increased by 35% with application of sunscreen 10 minutes prior to dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Estrogel&reg;: C",
"     <sub>",
"      avg",
"     </sub>",
"     on day 14 of therapy: 28.3 pg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Evamist&reg;: C",
"     <sub>",
"      avg",
"     </sub>",
"     : 19.6-30.9 pg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Menostar&reg;: C",
"     <sub>",
"      avg",
"     </sub>",
"     : 13.7 pg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Vivelle-Dot&reg;: C",
"     <sub>",
"      avg",
"     </sub>",
"     : 34-104 pg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vaginal: Femring&reg;: Rapid during the first hour following application, then declines to a steady rate over 3 months; C",
"     <sub>",
"      avg",
"     </sub>",
"     : 40.6-76 pg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely distributed; high concentrations in the sex hormone target organs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Bound to sex hormone-binding globulin and albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; partial metabolism via CYP3A4 enzymes; estradiol is reversibly converted to estrone and estriol; oral estradiol also undergoes enterohepatic recirculation by conjugation in the liver, followed by excretion of sulfate and glucuronide conjugates into the bile, then hydrolysis in the intestine and estrogen reabsorption. Sulfate conjugates are the primary form found in postmenopausal women. With transdermal application, less estradiol is metabolized leading to higher circulating concentrations of estradiol and lower concentrations of estrone and conjugates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Femtrace&reg;: 21-26 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Oral: Femtrace&reg;: 0.4-0.75 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine (as estradiol, estrone, estriol and their glucuronide and sulfate conjugates)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14746/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Chlebowski RT, Aragaki AK, et al, \"Conjugated Equine Oestrogen and Breast Cancer Incidence and Mortality in Postmenopausal Women With Hysterectomy: Extended Follow-Up of the Women's Health Initiative Randomised Placebo-Controlled Trial,\"",
"      <i>",
"       Lancet Oncol,",
"      </i>",
"      2012,13(5):476-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14746/abstract-text/22401913/pubmed\" id=\"22401913\" target=\"_blank\">",
"        22401913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Limacher M, Assaf AR, et al, \"Effects of Conjugated Equine Estrogen In Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial.\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 291(14):1701-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14746/abstract-text/15082697/pubmed\" id=\"15082697\" target=\"_blank\">",
"        15082697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chlebowski RT, Kuller LH, Prentice RL, et al, \"Breast Cancer After Use of Estrogen Plus Progestin in Postmenopausal Women,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(6):573-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14746/abstract-text/19196674/pubmed\" id=\"19196674\" target=\"_blank\">",
"        19196674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSancho MT, Dorff T, and Rand JH, \"Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,\"",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 2010, 21(6):534-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14746/abstract-text/20581664/pubmed\" id=\"20581664\" target=\"_blank\">",
"        20581664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ellis MJ, Gao F, Dehdashti F, et al, &ldquo;Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor-Positive, Aromatase Inhibitor-Resistant Advanced Breast Cancer: A Phase 2 Randomized Study,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2009, 302(7):774-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14746/abstract-text/19690310/pubmed\" id=\"19690310\" target=\"_blank\">",
"        19690310",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hsia J, Langer RD, Manson JE, et al, \"Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2006, 166(3):357-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14746/abstract-text/16476878/pubmed\" id=\"16476878\" target=\"_blank\">",
"        16476878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hulley S, Grady D, Bush T, et al, &ldquo;Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 280(7):605-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14746/abstract-text/9718051/pubmed\" id=\"9718051\" target=\"_blank\">",
"        9718051",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      M&oslash;rch LS, L&oslash;kkegaard E, Andreasen AH, et al, &ldquo;Hormone Therapy and Ovarian Cancer,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2009, 302(3):298-305.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14746/abstract-text/19602689/pubmed\" id=\"19602689\" target=\"_blank\">",
"        19602689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Breast Cancer,&rdquo; Version 2.2010. Available at  file://www.nccn.org/professionals/physician_gls/PDF/breast.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Prostate Cancer,&rdquo; Version 3.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      North American Menopause Society [NAMS], \"The 2012 Hormone Therapy Position Statement of The North American Menopause Society,\"",
"      <i>",
"       Menopause",
"      </i>",
"      , 2012, 19(3):257-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14746/abstract-text/22367731/pubmed\" id=\"22367731\" target=\"_blank\">",
"        22367731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      North American Menopause Society (NAMS), ''The Role of Local Vaginal Estrogen for Treatment of Vaginal Atrophy in Postmenopausal Women: 2007 Position Statement of The North American Menopause Society,\"",
"      <i>",
"       Menopause",
"      </i>",
"      , 2007,14(3 Pt 1):355-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14746/abstract-text/17438512/pubmed\" id=\"17438512\" target=\"_blank\">",
"        17438512",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al, &ldquo;Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principle Results From the Women's Health Initiative Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(3):321-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14746/abstract-text/12117397/pubmed\" id=\"12117397\" target=\"_blank\">",
"        12117397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shumaker SA, Legault C, Rapp SR, et al, &ldquo;Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(20):2651-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14746/abstract-text/12771112/pubmed\" id=\"12771112\" target=\"_blank\">",
"        12771112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simon J, Nachtigall L, Ulrich LG, et al, \"Endometrial Safety of Ultra-Low-Dose Estradiol Vaginal Tablets,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2010, 116(4):876-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14746/abstract-text/20859151/pubmed\" id=\"20859151\" target=\"_blank\">",
"        20859151",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stallard S, Litherland JC, Cordiner CM, et al, &ldquo;Effect of Hormone Replacement Therapy on the Pathological Stage of Breast Cancer: Population Based, Cross Sectional Study,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 2000, 320(7231):348-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14746/abstract-text/10657329/pubmed\" id=\"10657329\" target=\"_blank\">",
"        10657329",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ulrich LS, Naessen T, Elia D, et al, &ldquo;Endometrial Safety of Ultra-Low-Dose Vagifem 10 microg in Postmenopausal Women With Vaginal Atrophy,&rdquo;",
"      <i>",
"       Climacteric",
"      </i>",
"      , 2010, 13(3):228-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14746/abstract-text/20423243/pubmed\" id=\"20423243\" target=\"_blank\">",
"        20423243",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al, \"Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(8):2055-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14746/abstract-text/21659542/pubmed\" id=\"21659542\" target=\"_blank\">",
"        21659542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weisberg E, Ayton R, Darling G, et al, &ldquo;Endometrial and Vaginal Effects of Low-Dose Estradiol Delivered by Vaginal Ring or Vaginal Tablet,&rdquo;",
"      <i>",
"       Climacteric",
"      </i>",
"      , 2005, 8(1):83-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/25/14746/abstract-text/15804736/pubmed\" id=\"15804736\" target=\"_blank\">",
"        15804736",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9120 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-3C5F28D7A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_25_14746=[""].join("\n");
var outline_f14_25_14746=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018272\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018338\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018339\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8090986\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018394\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018395\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018425\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018341\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018398\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018342\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018336\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018352\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018348\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018349\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018356\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018357\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018361\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018343\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018344\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018346\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018347\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018397\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018427\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018403\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018384\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11390228\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018378\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018385\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9120\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9120|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/58/38824?source=related_link\">",
"      Estradiol (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/35/35383?source=related_link\">",
"      Estradiol (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/1/38935?source=related_link\">",
"      Estradiol (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/34/40485?source=related_link\">",
"      Estradiol (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_25_14747="Intraarticular steroid toxicity";
var content_f14_25_14747=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F74660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F74660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Toxicity of intraarticular and soft tissue glucocorticoid injections",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Major",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cushing's syndrome (if frequency greater than one/month)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiologic deterioration of joints: \"steroid arthropathy;\" Charcot-like arthropathy; osteonecrosis-low incidence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iatrogenic infection-very low incidence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tendon rupture due to atrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fat necrosis or calcification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inadvertent injection of median nerve in carpal tunnel syndrome causing nerve atrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cataracts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Minor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postinjection flare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uterine bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Facial erythema",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_25_14747=[""].join("\n");
var outline_f14_25_14747=null;
var title_f14_25_14748="IASLC ATS ERS classification of lung adenocarcinoma in resection";
var content_f14_25_14748=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F66033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F66033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    IASLC ATS ERS classification of lung adenocarcinoma in resection specimens",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Preinvasive lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atypical adenomatous hyperplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Adenocarcinoma in situ (&le;3 cm, formerly BAC)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nonmucinous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mucinous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mixed mucinous/nonmucinous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Minimally invasive adenocarcinoma (&le;3 cm lepidic predominant tumor with &le;5 mm invasion)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonmucinous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mucinous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mixed mucinous/nonmucinous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Invasive adenocarcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lepidic predominant (formerly nonmucinous BAC pattern, with &gt;5 mm invasion)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acinar predominant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Papillary predominant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Micropapillary predominant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solid predominant with mucin production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Variants of invasive adenocarcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Invasive mucinous adenocarcinoma (formerly mucinous BAC)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colloid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fetal (low and high grade)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteric",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BAC: bronchioloalveolar carcinoma; IASLC: International Association for the Study of Lung Cancer; ATS: American Thoracic Society; ERS: European Respiratory Society.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6:244. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_25_14748=[""].join("\n");
var outline_f14_25_14748=null;
var title_f14_25_14749="Plasmin and thrombolysis";
var content_f14_25_14749=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The genesis and function of plasmin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 224px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The inactive precursor, plasminogen, acted upon by intrinsic and extrinsic activators, is converted to the active enzyme, plasmin. Plasmin digests fibrin, the predominant structural component of most intravascular thrombi in the arterial circulatory system, and, to a lesser degree, circulating fibrinogen. The lysis of fibrin generates cross-linked fibrin degradation products (XLFDP) while fibrinogen breakdown yields fibrin(ogen) degradation products (FDP). Thrombin, a pivotal enzyme in hemostatic and pathologic thrombotic processes, converts fibrinogen to fibrin, activates factor XIII (responsible for fibrin monomer crosslinking), and is also a potent platelet activator.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_25_14749=[""].join("\n");
var outline_f14_25_14749=null;
var title_f14_25_14750="Anti-IgE trial design";
var content_f14_25_14750=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71216&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Study design of pivotal trials of omalizumab",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 269px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The adult pivotal trials were identical in terms of study design and included four distinct phases: run-in, steroid-withdrawal, and double-blind extension. During the run-in phase, patients' standard therapy was switched to inhaled budesonide (BDP) and stabilized, which required the investigator to adjust the BDP dose so that the patients entered the core study period (steroid-stable phase) symptomatic yet exacerbation-free.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Busse, WJ. Anti-immunoglobulin E (Omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med 2001; 164:S12. Copyright &copy; 2001 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_25_14750=[""].join("\n");
var outline_f14_25_14750=null;
var title_f14_25_14751="DISH radiograph knee";
var content_f14_25_14751=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F70464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F70464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Knee involvement in diffuse idiopathic skeletal hypertrophy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 317px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral view of knee in patient with diffuse idiopathic skeletal hyperostosis (DISH). Radiograph shows osteophytes that arise from both the superior and inferior poles of the patella and from the tibial tuberosity (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Esdaile, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_25_14751=[""].join("\n");
var outline_f14_25_14751=null;
